

CONFERENCE REPORTS AND EXPERT PANEL



# Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine

M. Joannidis<sup>1\*</sup> , W. Druml<sup>2</sup>, L. G. Forni<sup>3</sup>, A. B. J. Groeneveld, P. M. Honore<sup>4</sup>, E. Hoste<sup>5</sup>, M. Ostermann<sup>6</sup>, H. M. Oudemans-van Straaten<sup>7</sup> and M. Schetz<sup>8</sup>

© 2017 The Author(s). This article is an open access publication

## Abstract

**Background:** Acute kidney injury (AKI) in the intensive care unit is associated with significant mortality and morbidity.

**Objectives:** To determine and update previous recommendations for the prevention of AKI, specifically the role of fluids, diuretics, inotropes, vasopressors/vasodilators, hormonal and nutritional interventions, sedatives, statins, remote ischaemic preconditioning and care bundles.

**Method:** A systematic search of the literature was performed for studies published between 1966 and March 2017 using these potential protective strategies in adult patients at risk of AKI. The following clinical conditions were considered: major surgery, critical illness, sepsis, shock, exposure to potentially nephrotoxic drugs and radiocontrast. Clinical endpoints included incidence or grade of AKI, the need for renal replacement therapy and mortality. Studies were graded according to the international GRADE system.

**Results:** We formulated 12 recommendations, 13 suggestions and seven best practice statements. The few strong recommendations with high-level evidence are mostly against the intervention in question (starches, low-dose dopamine, statins in cardiac surgery). Strong recommendations with lower-level evidence include controlled fluid resuscitation with crystalloids, avoiding fluid overload, titration of norepinephrine to a target MAP of 65–70 mmHg (unless chronic hypertension) and not using diuretics or levosimendan for kidney protection solely.

**Conclusion:** The results of recent randomised controlled trials have allowed the formulation of new recommendations and/or increase the strength of previous recommendations. On the other hand, in many domains the available evidence remains insufficient, resulting from the limited quality of the clinical trials and the poor reporting of kidney outcomes.

\*Correspondence: michael.joannidis@i-med.ac.at

<sup>1</sup> Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstasse 35, 6020 Innsbruck, Austria  
Full author information is available at the end of the article

Professor Groeneveld succumbed to a long illness which he fought with typical determination during the updating of this paper. He is sadly missed by us all.

**Keywords:** Acute kidney injury, Systematic review, Recommendations, Prevention, Volume expansion, Vasopressors

## Introduction

Acute kidney injury (AKI) affects up to 50% of critically ill patients and is independently associated with both short- and long-term morbidity and mortality [1–5]. The recent AKI-EPI study demonstrates that the most frequent causes of AKI in the critically ill are sepsis and hypovolaemia followed by nephrotoxic agents [6]. However, the cause of AKI is often multifactorial with pre-existing comorbidities further increasing the risk [3, 7–9].

The aim of this systematic review on the prevention and avoidance of further progression of AKI, by core members of the AKI section of the ESICM, is to provide:


- A critical evaluation of the existing evidence
- Give recommendations for clinical practice
- Update our previously published recommendations [10] and most recent guidelines [2, 11]

Our recommendations principally concern critically ill patients on the ICU but can also be applied to those planned to be admitted to the ICU such as high-risk surgical patients. By consensus, we primarily focussed on the role of volume expansion, diuretics, inotropes, vasopressors/vasodilators, hormones, nutrition, statins, sedatives and ischaemic preconditioning.

## Methodology

A systematic search of the literature was performed using the following databases: MEDLINE (1966 through March 2017), EMBASE (1980 through March 2017), CINAHL (1982 through March 2017), Web of Science (1955 through March 2017) and PubMed/PubMed CENTRAL to identify key studies, preferably randomised (placebo) controlled trials (RCT) and meta-analyses, addressing strategies to prevent AKI in *adult* critically ill patients. The following *clinical conditions* were considered: major surgery, critical illness, sepsis, shock and exposure to potentially nephrotoxic drugs. Specifically, renal transplantation, primary intrinsic renal disease (e.g. vasculitis) and hepatorenal syndrome were *not* considered. Search strategy and endpoints are available as electronic supplementary material (ESM\_1).

These recommendations are intended to provide clinical guidance and involved a modified Delphi process with a consensus meeting during the annual congresses of the European Society of Intensive Care Medicine in 2014, 2015 and 2016 followed by electronic-based/telephone



**Table 1** Criteria for best practice statements (Modified from Guyatt et al. [14])

Criteria for best practice statements	
1	Is the statement clear and actionable?
2	Is the message necessary?
3	Is the net benefit (or harm) unequivocal?
4	Is the evidence difficult to collect and summarize?
5	Is the rationale explicit?
6	Is this better to be formally GRADEd?

GRADE Gratings of Recommendations, Assessment, Development, and Evaluation

discussions. The quality of the evidence was judged by using the most recent GRADE (Gratings of Recommendations, Assessment, Development and Evaluation) criteria (Fig. 1) [12, 13]. The strength of the recommendations was classified as either strong (Grade 1) or weak (Grade 2). The degree (i.e. quality) of evidence for the recommendations was classified from high (A) to very low (D) according to factors including study design consistency of the results and directness of the evidence (Fig. 1, ESM\_1 Table S1). Evidence was downgraded where there was a risk of bias, inconsistency and imprecision. Evidence was upgraded for large effect size or significant dose–response gradient. If benefit or harm was unequivocal, but evidence was difficult to categorize by the GRADE methodology, we used best practice statements (BPSs), which represent ungraded strong recommendations [14] (Table 1).

We acknowledge that there may be circumstances whereby a recommendation cannot or should not be followed for an individual patient. Furthermore, interventions are generally investigated in isolation and not in combination, and as such recommendations relate to the *primary* intervention. Local clinical guidelines will govern the use of either a single intervention or a combination thereof.

## Volume expansion

### Recommendations

1. We *recommend* controlled fluid resuscitation in volume depletion, while, however, avoiding volume overload (Grade 1C).
2. We *recommend* against the use of starches (Grade 1A) as harm has been shown and *suggest* not using gelatine or dextrans for fluid resuscitation (Grade 2C).
3. We *recommend* correction of hypovolaemia/dehydration using isotonic crystalloids in patients receiving intravascular contrast media (Grade 1B).
4. We *recommend* regular monitoring of chloride levels and acid–base status in situations where chloride-rich solutions are used (BPS).
5. We *suggest* the use of balanced crystalloids for large volume resuscitation (Grade 2C).
6. We *suggest* using human serum albumin if a colloid is deemed necessary for the treatment of patients with septic shock (Grade 2C).
7. We *suggest* prophylactic volume expansion with crystalloids to prevent AKI by certain drugs (specified below) (BPS).
8. We *suggest* not delaying urgent contrast-enhanced investigations or interventions for potential preventative measures (BPS).

### Rationale

Relative and overt hypovolaemia are significant risk factors for development of AKI [15–18]. Timely fluid administration can restore circulating volume and renal perfusion, and may also reduce nephrotoxicity [19]. Volume replacement should be performed in a controlled, monitored fashion [20] as injudicious use of fluids carries its own inherent risks and may even contribute to AKI by increasing renal interstitial oedema and renal parenchymal pressure [21, 22]. Moreover, goal-directed therapy including the use of central venous pressure (CVP) as a resuscitation target has not been shown to prevent AKI in sepsis [23]. Volume replacement may be through crystalloids, colloids or their combination. Isotonic crystalloids represent the mainstay for correcting extracellular volume depletion with the caveat that hyperchloraemia is prevented to reduce potential renal vasoconstriction [24, 25]. Compared to crystalloids, colloids theoretically result in a greater plasma expansion. However, this effect depends on vascular barrier integrity which may be compromised in sepsis, particularly in the presence of vasoplegia [26, 27]. Consequently, the difference in required volumes for fluid resuscitation was minimal between crystalloids and colloids in large RCTs [28]. Moreover, large volume replacement with colloids alone risks hyperoncotic impairment of glomerular filtration [29, 30] and osmotic tubular damage [31, 32].

Available artificial colloids include gelatines, dextrans and until recently, starches. Gelatines have a moderate volume effect. Although risk of osmotic nephrosis with gelatines exists [33], the lack of clear clinical data on deleterious effects on renal function [34, 35] is offset by the possible prion transmission, histamine release and coagulopathy [36, 37]. Dextrans have reasonably high volume effects although anaphylaxis, coagulation disorders, osmotic nephrosis and AKI may occur with doses above 1.5 g/kg/day [38–41]. Human albumin (HA) is the only naturally occurring colloid and may appear attractive in hypooncotic hypovolaemia. It does increase the response to diuretics in patients with hypoalbuminaemia (e.g. nephrotic syndrome) [42, 43], has no negative effects on kidney function [44, 45], is safe [46] but can be costly.

### Clinical studies

Unsurprisingly, no studies have specifically addressed the effects of volume expansion compared to no volume resuscitation in overt hypovolaemia given the intuitive benefits of volume replacement. In severe sepsis, the beneficial effects of timely volume replacement on organ failure and mortality are well known, although the first RCT proving benefit of early volume resuscitation did not report kidney function [47]. On the other hand, preoperative volume expansion failed to reduce the incidence of postoperative AKI in 328 patients undergoing cardiac surgery [48], and a recent pilot RCT in sepsis could demonstrate that a volume-restrictive fluid protocol can reduce the incidence of AKI (RR 0.32; 95% CI 0.32–0.96) [49].

*Crystalloids* are considered the mainstay for volume expansion. Observational studies suggest an increased risk of AKI, renal replacement therapy (RRT) and mortality associated with the use of large volumes of normal saline (0.9% NaCl) as compared to so-called balanced solutions where chloride is partially replaced by another metabolizable anion [50–52]. An RCT comparing saline to a balanced solution (Plasmalyte®) in 2278 patients treated in four ICUs failed to show any superiority of balanced crystalloids regarding renal outcomes [53]. The study has been criticized for the limited fluid doses, inclusion of patients with low disease severity and the absence of data on chloride levels [54]. Similar results were observed in the pilot cluster-randomised, multiple-crossover SALT trial comparing saline to a balanced solution in 974 critically ill adults [55]. Again, only modest volumes were used, but increased rates of AKI were found in the normal saline group if larger volumes were administered (ESM\_2 Table S2). Studies on the effectiveness of sodium bicarbonate in preventing AKI, predominantly in patients undergoing cardiac surgery, have produced

conflicting results [56–59] as have consecutive meta-analyses [60–63].

The effect of *colloids* on renal function has undergone extensive scrutiny over the last decade. Large RCTs have substantiated the increased risk of AKI and RRT with use of starches [64] particularly in sepsis [65, 66], where they also lead to increased mortality [66] (ESM\_2 Table S3). This is verified by several meta-analyses [67–70] which underpin the abandoning of starches in critically ill patients [20, 71, 72]. Clinical data on the effects of gelatine on renal function are scarce. A recent meta-analysis, including three trials in 212 patients comparing gelatins with crystalloids or albumin, indicated a 35% increased relative risk of developing AKI with gelatine [73].

In contrast to artificial colloids, the administration of albumin appears to be safe for the kidney. A large RCT comparing normal saline to 4% HA in various clinical settings failed to demonstrate any differences in renal function [46] (ESM\_2 Table S3). In the ALBIOS trial the use of hyperoncotic (20%) albumin showed no effect on AKI or need for RRT in severe sepsis [74] but enabled a less positive fluid balance, confirming the results of another small trial [75]. A post hoc analysis of the ALBIOS trial showed survival benefit in septic shock [74] confirmed by meta-analyses [76, 77]. Hypoalbuminaemia in cardiac surgery might be another indication with improved fluid balance as well as a reduced rate of AKI being observed in a single-centre RCT of 220 patients [78].

Hypovolaemia may also contribute significantly towards drug-induced renal injury, although the available evidence supporting preventative hydration is only observational with no consensus related to timing, optimal volume and type of solution [19, 79, 80]. Prophylactic volume expansion has been shown to prevent harm from amphotericin B, antivirals including foscarnet, cidofovir and adefovir [81–83] as well as drugs causing crystal nephropathy such as indinavir, acyclovir, and sulfadiazine [84].

*Prophylactic* volume expansion is the mainstay of all recommendations to prevent contrast-associated AKI (CA-AKI) and is based on several randomised controlled studies performed in non-critically ill patients [85–90]. However, studies comparing hydration to no hydration are scarce [91]. Several pitfalls should be considered. First, CA-AKI is a diagnosis of exclusion and considerable variation exists with regard to the reported incidence rates, which are confounded by many factors such as transient fluctuations in measured serum creatinine in hospitalised patients and use of non-standardised diagnostic criteria [92]. Secondly, CA-AKI does not occur in patients without other risk factors for AKI, whereas most critically ill patients receiving intravascular contrast have other risk factors. Moreover, individuals with high risk for CA-AKI may not be given contrast. For these reasons

the role of CA-AKI is uncertain, particularly in an era where the use of low- or iso-osmotic agents and lower contrast volume administration have become standard practice. As indicated by an analysis of the Nationwide Inpatient Sample dataset comprising 5, 931,523 hospitalisations the OR for CA-AKI adjusted for age, sex, mechanical ventilation and combined co-morbidity score was 0.93 (0.88–0.97) [93]. Whereas a retrospective single-centre cohort study in 747 critically ill patients showed a rate of CA-AKI of 16% [94], matched cohort studies could not demonstrate a relationship with IV contrast for computed tomography in the ICU [95–97] or emergency department [98]. These findings are supported by a systematic review and Bayesian meta-analysis [99]. In the most recent propensity-matched cohort study, IV contrast was not associated with an increased risk of AKI or dialysis, but a subgroup with pre-CT eGFR of at most 45 ml/min/1.73 m<sup>2</sup> showed an increased risk of dialysis. The numbers in this subgroup were, however, small and subject to selection bias [97].

Although it seems prudent to correct hypovolaemia before contrast administration, prophylactic volume expansion in critically ill patients who are euvolaemic cannot be recommended on the basis of current data. No study demonstrates protection of pre-emptive volume expansion against CA-AKI in the critically ill. An RCT comparing hydration with isotonic bicarbonate versus normal saline failed to show superiority of either regimen but reported an excessively high rate of CA-AKI of 33% in both groups [100], which may be attributed to severity of illness in this critically ill cohort. Importantly, in patients with chronic kidney disease (CKD) undergoing percutaneous coronary intervention (PCI), hydration volumes above 11 ml/kg body weight (BW) were associated with continuously increased rates of AKI, requirement for RRT and mortality. The adjusted OR for developing AKI with hydration volumes greater than 25 ml/kg BW was 2.11 (CI 1.24–3.59) [101]. We recommend that the clinical decision to perform a contrast study in ICU patients must weigh the potential benefits with the low but probably not zero risk of CA-AKI.

## Diuretics

### Recommendations

1. We *recommend* against loop diuretics given solely for the prevention of acute kidney injury (Grade 1B).
2. We *suggest* using diuretics to control or avoid fluid overload in patients that are diuretic-responsive (Grade 2D).

### Rationale

Oligoanuria is frequently the first indicator of acute renal dysfunction. Intensivists frequently use loop diuretics in

a wide spectrum of AKI settings [102]. The rationale for using diuretics to ameliorate AKI includes prevention of tubular obstruction, reduction in medullary oxygen consumption and increase in renal blood flow as well as reducing fluid overload and venous congestion [103–105]. Although there is no single parameter for fluid overload, increased CVP [106], peripheral oedema [107] and/or increased intra-abdominal pressure [108, 109] may be used as surrogates. A recent study demonstrated that a urinary output of at least 100 ml/h following a test dose of 1.0–1.5 mg furosemide/kg BW predicted reduced progression to a higher stage of AKI in oliguric patients [110].

### Clinical studies

Use of conservative fluid management including diuretics has been investigated in only one large RCT in patients with acute lung injury (FACTT trial) which showed a tendency to reduced requirement of RRT [111].

In cardiac surgery either no protection [112] or elevated postoperative serum creatinine levels were found in patients receiving furosemide [113]. These findings were supported by a recent meta-analysis [114]. In patients with acute heart failure, diuretic therapy with higher doses was more effective at reducing clinical symptoms, but at the cost of decreased renal function [115]. To date four RCTs have examined the role of diuretics in *established* renal failure in the intensive care setting. No demonstrable improvements in clinically relevant outcomes, such as recovery of renal function or mortality, were observed [31, 116–118]. Other studies compared diuretics with dopamine or placebo, again with no perceived benefit [119–121]. Three meta-analyses confirmed that the use of diuretics in established AKI did not alter outcome but carried a significant risk of side effects such as hearing loss [122–124] (ESM\_2 Table S4).

### Vasopressors

#### Recommendations

1. We *recommend* titrating vasopressors to a mean arterial pressure (MAP) of 65–70 mmHg (Grade 1B) rather than a higher MAP target (80–85 mmHg) in patients with septic shock. However, for patients with chronic hypertension we *recommend* aiming for a higher target (80–85 mmHg) for renal protection in septic shock (Grade 1C).
2. We *recommend* lowering systolic pressure to 140–190 mmHg rather than to 110–139 mmHg in patients with acute cerebral haemorrhage with severe admission hypertension (Grade 1C).
3. If vasopressors are needed for treatment of hypotension, we *recommend* norepinephrine (along with correction of hypovolaemia) as the first-choice vasopres-

or to protect kidney function (Grade 1B) and *suggest* vasopressin in patients with vasoplegic shock after cardiac surgery (Grade 2C).

4. We *suggest* individualizing target pressure when pre-morbid blood pressure is available (BPS).

#### Rationale for MAP target

Preservation or improvement of renal perfusion can theoretically be achieved through increasing cardiac output by fluid resuscitation or inotropic drugs, through renal vasodilators or systemic vasopressors. Optimal target mean arterial pressure (MAP) was studied in a large open-label multicentre RCT randomising 777 patients with septic shock to resuscitation with a MAP target of either 80–85 mmHg or 65–70 mmHg [125]. In most of the patients the achieved MAP was above the set target. The study found no difference in mortality, incidence of AKI stage 2 (38.7% vs. 41.5%,  $p = 0.42$ ) or need for RRT (33.5% vs. 35.8%,  $p = 0.5$ ), but more atrial fibrillation in the high target group. However, in patients with known chronic hypertension a higher MAP resulted in a lower incidence of AKI stage 2 (38.9% vs. 52%,  $p = 0.02$ ) and less RRT (31.7% vs 42.2%,  $p = 0.046$ ); mortality was unchanged.

The safety of lowering systolic pressure was studied in a larger RCT in patients with acute cerebral haemorrhage with severe hypertension on admission [126]. Patients were randomised to a systolic blood pressure target of 110–139 or 140–179 mmHg. The primary endpoint (death or disability) was not different between groups. However, the rate of serious renal adverse events was higher in the lower target group (9% vs. 4%,  $p = 0.002$ ) (ESM\_2 Table S5).

#### Rationale for choice of vasopressor

*Norepinephrine* is the most commonly used vasopressor in patients with vasodilatory shock. A large RCT comparing dopamine to norepinephrine as initial vasopressor in patients with shock found no difference in mortality between randomised groups. However, norepinephrine was associated with less tachycardia in the first hours and was superior regarding survival in cardiogenic shock patients. In addition, there was a trend towards more RRT-free days through day 28 in the norepinephrine group [127].

*Vasopressin* or the analogue terlipressin may have a role in the treatment of norepinephrine-refractory shock [128]. Exogenous vasopressin has vasoconstrictive and antidiuretic properties and may increase glomerular filtration by preferential post-glomerular vasoconstriction [129]. In the largest RCT in septic shock (VASST trial), vasopressin reduced mortality in the subgroup with less severe shock, but not in the entire population. There were

no differences in RRT-free days [130]. However, in a secondary analysis, a reduced progression to higher stages of AKI could be demonstrated in the subgroup of patients with AKI stage 1 at baseline [131]. In a subsequent  $2 \times 2$  RCT in 409 patients with early septic shock (VANISH trial) [132], the use of vasopressin compared to norepinephrine did not affect the proportion of patients who never developed AKI stage 3 (57% vs. 59.2%), the number of AKI stage 3-free days [difference  $-4$  ( $-11$  to  $5$ )] or the incidence of AKI stage 3 [difference  $-5.1\%$  ( $-15.2$  to  $5.0$ )]. The use of vasopressin reduced the need for RRT (difference  $-9.9\%$  ( $-19.3$  to  $-0.6$ ), but only in non-survivors. A recent single-centre RCT in 300 patients with vasoplegic shock after cardiac surgery compared noradrenalin to vasopressin as first-choice vasopressor. The use of vasopressin was associated with less acute renal failure (10.3% vs. 35.8%,  $p < 0.0001$ ) and less RRT (2.7% vs. 13.9%,  $p = 0.0016$ ) [133]. This trial, however, had some design issues (e.g. change in primary outcome during the study) and requires confirmation. The studies are summarized in ESM\_2 Table S5.

## Use of vasodilators

### Recommendations

1. We *recommend* against low-dose dopamine for protection against AKI (Grade 1A).
2. We *recommend* not using levosimendan for renal protection in patients with sepsis (Grade 1B) and *recommend* against its use for renal protection in cardiac surgery patients with poor preoperative left ventricular function or needing postoperative haemodynamic support (Grade 1B).
3. We *suggest* not using fenoldopam or natriuretic peptides for renal protection in critically ill or cardiovascular surgery patients at risk of AKI (Grade 2B).

### Rationale

Early in the course of ischaemic AKI, renal blood flow (RBF) falls because of stimulation of the sympathetic nervous system and the release of vasoconstrictors such as endothelin, angiotensin II and vasoconstrictive prostaglandins [134, 135]. In contrast, during septic AKI global RBF seems to be well preserved [136, 137]. The main perfusion problem during sepsis seems to occur at the microvascular level and regionally in the outer medulla [138]. When using vasodilators for kidney protection, several issues should be considered. First, vasodilators may cause hypotension by counteracting compensatory vasoconstriction, thus unmasking occult hypovolaemia. Hypotension may further compromise renal perfusion and correction of hypovolaemia is therefore crucial. Second, as a result of endothelial damage, nitric oxide (NO)-dependent vasodilators seem to be ineffective [135].

Third, timing may be crucial, since delayed administration reduces effectiveness as a result of occlusion of the microcirculation [139].

### Clinical studies

*Low-dose* or '*renal*' dose dopamine has been advocated in the past to prevent selective renal vasoconstriction in a variety of conditions. This may not be the case in complex clinical conditions, where low-dose dopamine may even worsen renal perfusion [140]. Several meta-analyses have concluded that '*renal-dose*' dopamine has no benefit in either preventing or ameliorating AKI in the critically ill [141–143], the latest [141] being presented in ESM\_2 Table S6.

*Fenoldopam* is a pure dopamine- $A_1$  receptor agonist providing systemic and renal vasodilation and natriuresis, and it has been studied in cardiovascular surgery and critically ill patients. Two older meta-analyses, one including 1290 critically ill and surgical patients (mainly cardiovascular) from 16 RCTs and the other including 1059 cardiac surgery patients from 13 (partially overlapping) RCTs and case-matched studies, reported that the use of fenoldopam reduced the incidence of AKI, need for RRT and hospital mortality [144]. Most studies were small with a moderate to high risk of bias and in the second meta-analysis 30% of the included studies were abstracts. The two most recent meta-analyses in cardiac surgery and major surgery used stricter inclusion criteria [145, 146] and only found a lower risk for AKI, but not for RRT or death. In addition, both showed an increased risk of hypotension and most included studies had a high risk of bias due to low sample size and fragility index, and use of different definitions for AKI. The most recent and largest RCT in *post cardiac surgery* patients with AKIN stage I [147] did not show any renal protection or clinical benefit from the use of fenoldopam, while fenoldopam conferred more hypotension. (Studies are summarized in ESM\_2 Table S7).

*Atrial natriuretic peptide (ANP)* is produced by cardiac atria in response to an acute increase in stretch and/or pressure and induces afferent dilatation and efferent vasoconstriction, thereby increasing glomerular filtration and urinary sodium excretion with a dose-dependent hypotensive effect [148, 149]. *B-type (brain) natriuretic peptide (BNP)* is primarily produced in the cardiac ventricles and has similar effects [150, 151].

The two most recent meta-analyses including RCTs in the cardiac and cardiovascular surgery population found that the prophylactic infusion of low-dose ANP reduced postoperative peak creatinine [152] and the need for RRT [152–154]. However, the latter was based on only 24 cases of RRT in 563 patients. No effect was found in established AKI and high-dose ANP was associated with more

frequent adverse effects (arrhythmias, hypotension) [154]. Two later RCTs on the use of ANP in aortic arch ( $n = 42$ ) and high-risk cardiac surgery ( $n = 367$ ) confirmed a reduction in postoperative AKI and need for RRT (0/183 vs. 7/184,  $p = 0.015$ ) [155, 156] (ESM\_2 Table S8).

A recent meta-analysis including 15 RCTs in 9623 patients with acute decompensated heart failure showed that the use of BNP (nesiritide) was associated with worsening renal function: RR 1.08 (1.01–1.15), especially in the subgroup receiving a high dose ( $>0.01 \mu\text{g}/\text{kg}/\text{min}$ ) and in patients without CKD [157].

In general, most BNP trials were small, not powered for the endpoints RRT or mortality, of poor quality with low fragility index; inclusion criteria varied and results were heterogeneous. Furthermore, hypotension and arrhythmia were frequently reported. A small subgroup meta-analysis on BNP in cardiovascular surgery also showed no benefit [152] (ESM\_2 Table S8).

The calcium sensitizer *levosimendan* has inodilator, cardioprotective and anti-inflammatory effects [158, 159]. In a recent meta-analysis of RCTs in the cardiac surgery population (13 trials, 1345 patients), the use of *levosimendan* decreased the risk of AKI [OR 0.51 (0.24–0.79)], the need for RRT [OR 0.43 (0.25–0.76)] and mortality [OR 0.41 (0.27–0.62)] [160]. The last meta-analysis of RCTs in the critically ill population with or at risk of AKI (33 RCTs, 3867 patients) found that, compared to placebo or another inotrope, *levosimendan* decreased the risk of AKI [RR 0.79 (0.63–0.99)] and the need for RRT [RR 0.52 (0.32–0.86)]. When limiting the analysis to high-quality studies, the difference in need for RRT between groups failed to reach significance [RR 0.41 (0.15–1.12)] [161]. Studies in both meta-analyses were small, there was some heterogeneity, AKI was not always a predefined endpoint, different definitions of AKI were used and there might have been some outcome reporting bias.

Three large placebo-controlled RCTs have recently been published. In patients with sepsis the use of *levosimendan* was not beneficial in terms of a reduction of renal SOFA, need for RRT [OR 0.99 (0.66–1.49)] or mortality [OR 1.19 (0.82–1.72)], while its use was associated with more adverse events [162]. In 882 patients with left ventricular dysfunction undergoing cardiac surgery, *levosimendan* had no effect on mortality or need for RRT [163]. No effect on AKI and RRT was seen when *levosimendan* was given for haemodynamic support after cardiac surgery in 506 patients [164] (ESM\_2 Table S9).

## Sedation

### Recommendations

1. On the basis of current data no recommendation can be given, although it appears that shorter seda-

tion using propofol or dexmedetomidine may have several advantages, possibly reducing the rate of AKI (BPS).

### Rationale

Sedation is necessary in many critically ill patients and this may affect cardiac function and/or vascular tone with renal consequences. In animal models propofol reduced markers of oxidative stress in the kidney [165, 166] and dexmedetomidine caused diuresis through reducing vasopressin secretion, enhancing renal blood flow and hence glomerular filtration [167] and showed renal protection [168–171].

### Clinical studies

*Propofol* is commonly used as anaesthetic and for sedation in the intensive care unit [172]. The “propofol infusion syndrome” comprises myopathy, rhabdomyolysis, hyperkalaemia and AKI [173, 174]. On the basis of the data from case reports/series, it is recommended to administer propofol for a maximum of 48 h and a maximum dose of 4 mg/kg/h [175]. On the other hand, a recent propensity-matched cohort study in critically ill patients showed reduced risk of AKI and need for RRT in patients sedated with propofol as compared to midazolam [176]. Furthermore a small RCT including 112 patients undergoing valvular heart surgery showed less AKI and significantly lower cystatin C levels in the group treated with propofol as compared to sevoflurane [177]. However, the fact that remote ischaemic preconditioning showed less effect if patients were treated with propofol leaves uncertainty about the protective effect of propofol on the kidney [178].

$\alpha$ -2 Adrenergic agonists have multiple pharmacodynamic effects [179]. In a placebo-controlled double-blind RCT *dexmedetomidine* demonstrated significant diuretic effects, with an almost 75% increase in diuresis after cardiac surgery, but did not affect renal function per se [180]. Observational trials indicated protection of kidney function after cardiac surgery [181] but not when used for sedation during lung cancer resection [182]. A placebo-controlled study in 90 patients undergoing coronary artery bypass graft (CABG) showed a dose-dependent reduction of NGAL levels with dexmedetomidine used for postoperative sedation [183]. Another RCT in 200 patients showed that dexmedetomidine for 24 h at 0.4  $\mu\text{g}/\text{kg}/\text{h}$  from start of anaesthesia resulted in reduced rate of AKI, morbidity and length of stay in the ICU [184] (ESM\_2 Table S10).

Alltogether, the data for non-benzodiazepine sedatives, especially dexmedetomidine, are promising but currently not sufficiently convincing to give a clear recommendation.

## Hormonal manipulation

### Recommendations

1. We *suggest* targeting a blood glucose level at least below 180 mg/dL (10 mmol/l) for the prevention of hyperglycaemic kidney damage in the general ICU population (Grade 2B).
2. We *suggest* not using erythropoietin (Grade 2B) or steroids (Grade 2B) for prevention of acute kidney injury.

### Rationale

In critical illness hyperglycaemia has been associated with adverse outcomes [185, 186] attributed to oxidative stress, endothelial dysfunction, alterations in haemostasis, immune dysregulation and mitochondrial dysfunction. The anti-inflammatory effect of steroids may attenuate the inflammatory component of AKI pathogenesis. Erythropoietin (EPO), besides being a haematopoietic growth factor, also has tissue-protective properties by decreasing apoptosis and inflammation and by promoting neovascularization and tissue regeneration.

### Clinical studies

A large prospective RCT in 1548 surgical ICU patients compared *tight glucose control (TGC)* with insulin (target blood glucose 80–110 mg/dL) to standard care (insulin when blood glucose is greater than 200 mg/dL resulting in a mean blood glucose of 150–160 mg/dL) and showed not only an improved survival rate but also a 41% reduction in AKI requiring RRT [187]. Additionally, TGC also reduced the number of patients with peak plasma creatinine greater than 2.5 mg/dL by 27%. A subsequent study in the medical ICU of the same hospital, including many patients that already had AKI on admission, did not confirm the effect on survival or need for RRT, but showed a 34% reduction in AKI, defined as a doubling of serum creatinine compared with the admission level [188]. A combined analysis of both studies showed a more pronounced renal protection when normoglycaemia was achieved [189].

More recent RCTs in septic [65] and general [190–194] ICU patients (some of which had to be stopped early because of hypoglycaemia) including a large adequately powered multicentre trial in Australia and New Zealand (NICE-SUGAR) [191] did not confirm the renoprotective effect. The latter even found a higher mortality in patients treated with TGC compared to an intermediate level. Clinicians should, however, be aware of important differences between these landmark trials, such as the glycaemic target in the control group, the nutritional strategy and the methods used to measure blood glucose levels [195]. The most recent meta-analysis on this issue did not find a mortality benefit [RR 1.06 (0.99–1.13)]

[196] of TGC nor a renoprotective effect (evaluated by the need for RRT only) [RR 0.96 (0.83–1.11)] [196] (ESM\_2 Table S11).

A major obstacle to the broad implementation of TGC is the increased risk of hypoglycaemia. Patients with AKI are at particular risk [197]. On the other hand, a causal relationship between a short-lasting iatrogenic hypoglycaemia in the monitored setting of an ICU and outcome remains controversial [198–200]. If clinicians decide to adopt TGC strategies, fluctuations in glucose levels should be minimized and reliable tools should be employed to measure blood glucose [195]. Because of the risk of hypoglycemia, current guidelines suggest more moderate blood glucose targets (less than 180 mg/dL [20], less than 150 mg/dl [52], 140–180 mg/dL [201]) in critically ill patients, although these targets have not been formally compared with tolerating hyperglycaemia [202] (ESM\_2 Table S11).

A recent large RCT ( $n = 4494$ ) demonstrated no significant effect of the intraoperative administration of *dexamethasone* on a composite endpoint of major complications after cardiac surgery. The RR for RIFLE-Failure was 0.7 (0.44–1.14) [203]. A post hoc analysis of this trial showed a beneficial effect on the need for RRT (RR 0.44 (0.19–0.96)), an effect that was mainly seen in patients with eGFR less than 15 ml/min/1.73 m<sup>2</sup> and remains to be confirmed [204]. Another placebo-controlled RCT in 7507 patients found no effect of methylprednisolone on the incidence of AKI stage 3 after cardiac surgery [205].

Prospective randomised placebo-controlled trials on the renoprotective effect of *erythropoietin* have mainly been performed in the setting of cardiac surgery [206–210]. A recent meta-analysis (5 studies, 423 patients) found no effect of erythropoietin on the incidence of AKI: RR 0.64 (0.35–1.16). Surprisingly, a preplanned subgroup analysis found a significant reduction of AKI in patients without high risk for AKI: RR 0.37 (0.24–0.61;  $p < 0.0001$ ) [211]. Similar results were obtained in the most recent meta-analysis, which in addition showed more protection with pre-anaesthetic administration [212]. Another RCT in cardiac surgery including 75 patients with pre-existing renal impairment found no differences in postoperative levels of serum creatinine, cystatin C or NGAL [213]. A second meta-analysis (on a total of 2759 patients) that also included studies in ICU patients [214, 215] likewise did not establish a renoprotective effect of erythropoietin: incidence of AKI RR 0.72 (0.79–1.19); dialysis requirement RR 0.72 (0.31–1.70), mortality RR 0.96 (0.78–1.18), all without significant heterogeneity amongst studies [216]. It should, however, be emphasized that in the largest study in ICU patients [215] AKI was only reported as an adverse effect and not clearly defined. Two more recent RCTs in the setting of



thoracic aortic surgery [217] and contrast administration in diabetics [218] confirmed the absence of beneficial effect of EPO on the incidence of AKI or need for RRT in critically ill patients (ESM\_2 Table S12).

## Metabolic interventions

### Recommendations

1. We *recommend* not using high-dose IV selenium for renal protection in critically ill patients (1B).
2. We *suggest* not using *N*-acetylcysteine to prevent contrast-associated AKI in critically ill patients because of conflicting results and possible adverse effects (Grade 2B).
3. We *suggest* that all patients with or at risk of acute kidney injury have adequate nutritional support preferably through the enteral route (BPS).

### Rationale

Starvation accelerates protein breakdown and impairs protein synthesis in the kidney, whereas feeding might exert the opposite effects and promote renal regeneration. In animal experiments increased protein intake has been shown to reduce tubular injury [219, 220], and enteral versus parenteral nutrition improved the resolution of AKI [221]. On the other hand, amino acids infused before or during ischaemia may also enhance tubular damage and accelerate loss of renal function [222]. This may also extend to high-dose glutamine when given to patients during the injury phase of AKI [223]. Furthermore, brief periods of reduced food intake appear to increase resistance against ischaemia–reperfusion injury in rodents [224]. This “amino acid paradox” may be related to the increase in metabolic work for transport processes which may aggravate ischaemic injury. Enhanced autophagy, induced by nutrient deprivation and promoting the repair of cellular damage, may be an alternative explanation. In this context permissive underfeeding during the acute phase of critical illness may be protective against AKI.

One aspect of nutrition is the adequate supply of nutritional co-factors and antioxidants such as the glutathione precursor *N*-acetylcysteine (NAC), antioxidant vitamins (vitamin E ( $\alpha$ -tocopherol) and vitamin C (ascorbic acid)) as well as selenium. However, these antioxidants have also been investigated in pharmacological doses with the intention to provide protection against damage by oxygen radicals.

### Clinical studies

*Protein(s) and amino acids* augment renal perfusion and improve renal function, representing recruitment of “renal reserve capacity” [225]. An RCT investigating the

effects of daily intravenous amino acid supplementation up to 100 g/day in 424 critically ill patients could not find a significant effect on the duration of AKI despite an increase in eGFR in the treatment group [226]. Furthermore, there was a trend towards increased need for RRT which corresponds to findings from the EPaNIC trial where early parenteral nutrition increased the duration of RRT probably driven by higher urea levels [227]. Correspondingly, lower caloric intake (defined as receiving less than 60% of requirements, also called permissive underfeeding) has been found to be associated with a lower risk for RRT (RR 0.711, 95% CI 0.545–0.928) [228].

A host of RCTs have been performed comparing NAC to placebo or other interventions with or without hydration in non-critically ill patients receiving radiocontrast media [229–237]. Results are controversial as alluded to earlier but the latest meta-analysis assessing the efficacy of intravenous NAC only showed no reduction of AKI or RRT [238]. The ACT trial, currently the largest RCT including 2308 patients undergoing coronary and peripheral vascular angiography, failed to demonstrate any beneficial effect of NAC [239]. RCTs in the critically ill population are not available.

RCTs examining the role of NAC in the prevention of renal dysfunction in high-risk contexts like cardiac surgery showed controversial results [240–246] (ESM\_2 Table S13). In addition IV NAC may be harmful leading to allergic reactions [247] and decreased cardiac output or survival in patients with septic shock [248, 249].

A small RCT in 42 patients showed that *selenium* supplementation decreased the requirement for RRT from 43% to 14% in patients with SIRS [250]. These finding could, however, not be reproduced in consecutive trials [251] including two larger RCTs involving 249 and 1089 patients with sepsis [252, 253].

## Statins

### Recommendations

1. We *recommend* against the perioperative use of high-dose statins to prevent postoperative AKI in cardiac surgery (Grade 1A).
2. We *suggest* the short-term use of atorvastatin or rosuvastatin to prevent contrast-associated AKI in high-risk patients undergoing coronary contrast angiography (Grade 2B).

### Rationale

The pleiotropic effect of statins, including antioxidant, anti-inflammatory and antithrombotic effects, may contribute to nephroprotection [254].

### Clinical studies

*Statins* may have a beneficial role in high-risk patients exposed to contrast administration for angiography, as suggested by three recent RCTs [255–257]. In a multicentre trial in China, 2998 patients with type 2 diabetes or mild to moderate CKD undergoing coronary or peripheral arterial angiography were randomised to a 5-day course of rosuvastatin versus no statin [255]. The incidence of CA-AKI was significantly lower in those receiving rosuvastatin (2.3% vs. 3.9%, respectively,  $p = 0.01$ ). In a single-centre study [256], 504 statin-naïve patients with acute coronary syndrome (ACS) scheduled to undergo an early invasive strategy were randomised to high-dose rosuvastatin at the time of admission versus treatment with atorvastatin commenced at hospital discharge; 6.7% of patients in the early high-dose statin group developed CA-AKI compared to 15.1% in the control group. The 30-day rate of adverse cardiovascular and renal events was also significantly reduced in the rosuvastatin group (3.6% vs. 7.9%, respectively,  $p = 0.036$ ). An RCT in 410 CKD patients showed less CA-AKI in patients randomised to a single dose of atorvastatin within 24 h before contrast exposure compared to the control group (4.5% vs. 17.8%,  $p = 0.005$ ) [257]. Two more recent RCTs found similar effects of statins in diabetics with CKD [258, 259]. These positive findings were confirmed by several meta-analyses combining studies in patients undergoing coronary angiography [260–263] (ESM\_2 Table S14). One of these meta-analyses concluded that short-term, pre-procedural, intensive statin treatment only reduced CA-AKI in ACS patients and recommended further studies in non-ACS patients [264]. This meta-analysis, however, did not include the largest RCT [255]. Although, these results lend support to the short-term use of statins before procedures involving intra-arterial contrast exposure in patients with coronary artery disease with or without diabetes and/or CKD, it must be considered that most of the studies were performed outside the ICU, thereby warranting downgrading of the level of evidence.

In patients undergoing cardiac surgery, two large meta-analyses including data from observational studies found conflicting evidence regarding the role of preoperative statin in preventing postoperative AKI [265, 266], and a Cochrane analysis of small RCTs found no effect [267]. Two recent placebo-controlled RCTs investigated the effects of perioperative high-dose atorvastatin (i.e. 80 mg, followed by 40 mg daily) in elective cardiac surgery [268] and valvular heart surgery [269] and showed no renal benefit. Furthermore, in the largest trial,

statin-naïve patients with CKD had a higher incidence of AKI when treated with statin [268] (ESM\_2 Table S15). Finally, an even larger placebo-controlled RCT in 1922 cardiac surgery patients that included AKI as a secondary outcome demonstrated renal harm in those receiving rosuvastatin 20 mg/day in the perioperative period [270].

### Remote ischaemic preconditioning

#### Recommendations

1. We *suggest* not using remote ischaemic preconditioning for prevention of AKI in critically ill patients (Grade 2A).

#### Rationale

Remote ischaemic preconditioning (RIPC) or several short cycles of limb ischaemia is achieved through inflation of a blood pressure cuff. The mechanism by which RIPC prevents AKI is incompletely understood.

#### Clinical studies

In cardiac surgery several single-centre RCTs demonstrated reduced incidence of AKI and need for RRT [271–273]. However, several others, including four larger and multicentric RCTs [274–277] did not confirm these beneficial effects, nor was a change in creatinine or mortality demonstrated. The conflicting results in cardiac surgery may be explained by inclusion of low-risk patients in trials that showed no benefit, and the use of propofol and opioids, treatments that may blunt the beneficial effects of RIPC.

In 13 recent meta-analyses the effect of RIPC was evaluated in different cohorts and definitions of AKI [178, 278–289]. Though several meta-analyses found a reduction of AKI [278, 279, 281–284, 286, 287, 289, 290] this was restricted to stage 1 AKI [289], or subgroups such as percutaneous coronary interventions [278, 279], or cardiac surgery with propofol-free anaesthesia [283]. The meta-analyses are limited by risk of bias, heterogeneity in definitions of AKI, low event rates and underestimation of influence of co-morbidities [283, 289]. Finally, a Cochrane review including studies on patients undergoing surgery could not show a benefit on renal outcomes [178] (ESM\_2 Table S16).

In summary, the effects by which RIPC prevents AKI are incompletely understood. RIPC for prevention of AKI has mainly been evaluated in cardiovascular surgery and after contrast administration. Larger studies and meta-analyses are not consistent in demonstrating a preventive effect of RIPC for AKI.

## AKI care bundles

### Recommendations

1. We *suggest* using the KDIGO recommendations to reduce the incidence of AKI after cardiac surgery (Grade 2C).
2. The use of AKI care bundles outside the intensive care unit has some benefits, including the potential to improve the outcome of AKI (BPS).

### Rationale

Care bundles have been proposed as tools to improve the quality of care and outcome of patients with AKI. Ideally, they should contain a small set of practices, processes or treatments that are evidence-based, endorsed and/or recommended by guidelines and broadly accepted as appropriate and/or standard care by local stakeholders. They are designed such that if one element is not implemented, the remaining elements are not impacted.

### Clinical studies

Outside the critical care setting, different AKI care bundles have been implemented with variable improvement in clinical care, more efficient resource use and potentially improved outcomes, especially if combined with educational measures and electronic alerting [291–293]. To date, care bundles comprising the KDIGO recommendations have only been investigated in one study including 274 cardiac surgery patients at high risk for AKI as determined by AKI biomarkers. The study showed less postoperative AKI (although mainly by the urine output criteria) without, however, influencing any major patient-centred outcome like RRT or renal recovery at day 30 [294]. The treatment strategy included avoidance of nephrotoxins and hyperglycaemia as well as applying goal-directed haemodynamic optimisation. It is unclear which element was effective because goal-directed therapy (GDT) neither prevented AKI nor reduced the need for RRT in septic shock, as shown by a secondary analysis [23] and a meta-analysis of three recent large RCTs [295], but avoiding nephrotoxins, hyperglycaemia and hypovolaemia seems to be reasonable.

### Conclusions and summary

Prompt resuscitation of the circulation with fluids, vasopressors and inotropes remains the cornerstone in the prevention of AKI. Volume expansion with isotonic crystalloids is only recommended in states of true and suspected hypovolaemia. Uncontrolled volume expansion and the use of starches and dextrans should be avoided. Following or together with fluid resuscitation hypotensive patients should be given a vasoconstrictor, preferably norepinephrine, and titrated individually with a target MAP of 65–70 mmHg being adequate in

most individuals without pre-existing chronic hypertension. The potential role of vasopressin requires further investigation. Together with these measures a review of all medications with the cessation of those known to be nephrotoxic is mandatory. Diuretics should not be used for prevention of AKI alone but may benefit the kidney by relieving renal congestion. Frank hyperglycaemia should be avoided. The effect of statins appears to depend on the setting, with promising results in contrast administration but no effect or even harm in cardiac surgery. There is low-level evidence that the choice of the sedative may impact kidney function. The conflicting results on ischaemic preconditioning preclude a firm recommendation.

Heterogeneous definitions of AKI still hamper comparison of different studies, despite the commendable efforts by the ADQI, AKIN and KDIGO working groups [2, 296, 297]. In addition, AKI is frequently reported as a secondary outcome. Although several RCTs have fuelled the literature on prevention of AKI over the past 4–5 years, the available evidence remains insufficient. Many recommendations are therefore formulated as weak with low grade quality of evidence. More high-quality studies with consensus AKI definitions will be required to fill the knowledge gaps.

### Electronic supplementary material

The online version of this article (doi:10.1007/s00134-017-4832-y) contains supplementary material, which is available to authorized users.

### Acknowledgements

Open access funding provided by University of Innsbruck and Medical University of Innsbruck.

### Author details

<sup>1</sup> Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Anichstasse 35, 6020 Innsbruck, Austria. <sup>2</sup> Department of Internal Medicine III, University Hospital Vienna, Vienna, Austria. <sup>3</sup> Department of Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey and Surrey Perioperative Anaesthesia and Critical Care Collaborative Research Group (SPACeR), Intensive Care Unit, Royal Surrey County Hospital NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, United Kingdom. <sup>4</sup> Department of Intensive Care, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Brussels, Belgium. <sup>5</sup> Department of Intensive Care Medicine, Ghent University Hospital, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium. <sup>6</sup> Department of Critical Care and Nephrology, Guy's and St Thomas' Hospital, London, United Kingdom. <sup>7</sup> Department of Adult Intensive Care, VU University Medical Centre, De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands. <sup>8</sup> Clinical Department and Laboratory of Intensive Care Medicine, Division of Cellular and Molecular Medicine, KU Leuven University, Leuven, Belgium.

### Compliance with ethical standards

### Conflicts of interest

MJ has received honoraria or research support from Baxter Healthcare Corp, AM-Pharma, CLS Behring, Fresenius and Astute Medical. WD declares no conflicts of interest. LF has received honoraria and research support from Astute Medical, Fresenius, Baxter Gambro Renal and Orthoclinical Diagnostics. PH had received research grants from Baxter, AM Pharma, Bellco, and Pfizer EH received speaker's fees from Alexion and Astute Medical, and a research grant from Bellco. MO has received honoraria and research funding from Fresenius Medical Care and Baxter Gambro. HO has financial congress support from Dirinco (Netherlands) and speaker's honoraria from Fresenius and Gambro/Baxter. MS declares no conflicts of interest.

## Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Received: 10 April 2017 Accepted: 2 May 2017

Published online: 2 June 2017

## References

- Chertow GM, Burdick E, Honour M (2005) Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol* 16:3365–3370
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group (2012) KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl* 2:1–138
- Kane-Gill SL, Sileanu FE, Murugan R, Trietley GS, Handler SM, Kellum JA (2015) Risk factors for acute kidney injury in older adults with critical illness: a retrospective cohort study. *Am J Kidney Dis* 65:860–869
- Kirwan CJ, Blunden MJ, Dobbie H, James A, Nedungadi A, Prowle JR (2015) Critically ill patients requiring acute renal replacement therapy are at an increased risk of long-term renal dysfunction, but rarely receive specialist nephrology follow-up. *Nephron* 129:164–170
- Joannidis M, Metnitz B, Bauer P, Schusterschitz N, Moreno R, Druml W, Metnitz PG (2009) Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. *Intensive Care Med* 35:1692–1702
- Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA (2015) Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. *Intensive Care Med* 41:1411–1423
- Piccinni P, Cruz DN, Gramaticopolo S, Garzotto F, Dal Santo M, Aneloni G, Rocco M, Alessandri E, Giunta F, Michetti V, Iannuzzi M, Belluono Anello C, Brienza N, Carlini M, Pelaia P, Gabbanelli V, Ronco C, Investigators N (2011) Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFRONT). *Minerva Anestesiol* 77:1072–1083
- Srisawat N, Sileanu FE, Murugan R, Bellomod R, Calzavacca P, Cartin-Ceba R, Cruz D, Finn J, Hoste EE, Kashani K, Ronco C, Webb S, Kellum JA, Acute Kidney Injury-6 Study Group (2015) Variation in risk and mortality of acute kidney injury in critically ill patients: a multicenter study. *Am J Nephrol* 41:81–88
- Bell S, Dekker FW, Vadeloo T, Marwick C, Deshmukh H, Donnan PT, Van Diepen M (2015) Risk of postoperative acute kidney injury in patients undergoing orthopaedic surgery—development and validation of a risk score and effect of acute kidney injury on survival: observational cohort study. *BMJ* 351:h5639
- Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, Ronco C, Schetz MR, Woittiez AJ, Critical Care Nephrology Working Group of the European Society of Intensive Care Medicine (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM. *Intensive Care Med* 36:392–411
- Ichai C, Vinsonneau C, Souweine B, Armando F, Canet E, Clec'h C, Constantin JM, Darmon M, Duranteau J, Gaillot T, Garnier A, Jacob L, Joannes-Boyau O, Juillard L, Journois D, Lautrette A, Muller L, Legrand M, Lerolle N, Rimmelé T, Rondeau E, Tamion F, Walrave Y, Velly L, Société française d'anesthésie et de réanimation (Sfar), Société de réanimation de langue française (SRLF), Groupe francophone de réanimation et urgences pédiatriques (GFRUP), Société française de néphrologie (SFN) (2016) Acute kidney injury in the perioperative period and in intensive care units (excluding renal replacement therapies). *Ann Intensive Care* 6:48
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 336:924–926
- Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 64:395–400
- Guyatt GH, Schunemann HJ, Djulbegovic B, Akl EA (2015) Guideline panels should not GRADE good practice statements. *J Clin Epidemiol* 68:597–600
- de Mendonca A, Vincent JL, Suter PM, Moreno R, Dearden NM, Antonelli M, Takala J, Sprung C, Cantraine F (2000) Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. *Intensive Care Med* 26:915–921
- Guerin C, Girard R, Selli JM, Perdrix JP, Ayzac L (2000) Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Rhone-Alpes Area Study Group on Acute Renal Failure. *Am J Respir Crit Care Med* 161:872–879
- Schwilk B, Wiedeck H, Stein B, Reinelt H, Treiber H, Bothner U (1997) Epidemiology of acute renal failure and outcome of haemodiafiltration in intensive care. *Intensive Care Med* 23:1204–1211
- Himmelfarb J, Joannidis M, Molitoris B, Schietz M, Okusa MD, Warnock D, Laghi F, Goldstein SL, Prielipp R, Parikh CR, Pannu N, Lobo SM, Shah S, D'Intini V, Kellum JA (2008) Evaluation and initial management of acute kidney injury. *Clin J Am Soc Nephrol* 3:962–967
- Joannidis M (2004) Drug-induced renal failure in the ICU. *Int J Artif Organs* 27:1034–1042
- Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerf B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellingham GJ, Bernard GR, Chiche JD, Cooper Smith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP (2017) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 43:304–377
- Prowle JR, Kirwan CJ, Bellomo R (2014) Fluid management for the prevention and attenuation of acute kidney injury. *Nat Rev Nephrol* 10:37–47
- Ostermann M, Straaten HM, Forni LG (2015) Fluid overload and acute kidney injury: cause or consequence? *Crit Care* 19:443
- Kellum JA, Chawla LS, Keener C, Singbartl K, Palevsky PM, Pike FL, Yealy DM, Huang DT, Angus DC, ProCESS and ProGrESS-AKI Investigators (2016) The effects of alternative resuscitation strategies on acute kidney injury in patients with septic shock. *Am J Respir Crit Care Med* 193:281–287
- Chowdhury AH, Cox EF, Francis ST, Lobo DN (2012) A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and Plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. *Ann Surg* 256:18–24
- Wilkes NJ, Woolf R, Mutch M, Mallett SV, Peachey T, Stephens R, Mythen MG (2001) The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. *Anesth Analg* 93:811–816
- Alphonsus CS, Rodseth RN (2014) The endothelial glycocalyx: a review of the vascular barrier. *Anaesthesia* 69:777–784
- Chappell D, Jacob M (2014) Role of the glycocalyx in fluid management: small things matter. *Best Pract Res Clin Anaesthesiol* 28:227–234
- Perner A, Prowle JR, Joannidis M, Young P, Hjortrup PB, Pettilä V (2017) Fluid management in acute kidney injury. *Intensive Care Med*. doi:10.1007/s00134-017-4817-x
- Horgan KJ, Ottaviano YL, Watson AJ (1989) Acute renal-failure due to mannitol intoxication. *Am J Nephrol* 9:106–109
- Rozich JD, Paul RV (1989) Acute renal failure precipitated by elevated colloid osmotic pressure. *Am J Med* 87:359–360

31. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. *Lancet* 342:248–249
32. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P (1996) Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. *Lancet* 348:1620–1622
33. Skinsnes OK (1947) Gelatin nephrosis; renal tissue changes in man resulting from the intravenous administration of gelatin. *Surg Gynecol Obstet* 85:563–571
34. Beyer R, Harmening U, Rittmeyer O, Zielmann S, Mielck F, Kazmaier S, Kettler D (1997) Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. *Brit J Anaesth* 78:44–50
35. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L (2001) Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. *Lancet* 357:911–916
36. Mardel SN, Saunders FM, Allen H, Menezes G, Edwards CM, Ollershaw L, Baddeley D, Kennedy A, Ibbotson RM (1998) Reduced quality of clot formation with gelatin-based plasma substitutes. *Br J Anaesth* 80:204–207
37. Tabuchi N, deHaan J, Huet RCGG, Boonstra PW, vanOeveren W (1995) Gelatin use impairs platelet adhesion during cardiac surgery. *Thromb Haemostasis* 74:1447–1451
38. Kurnik BR, Singer F, Groh WC (1991) Case report: dextran-induced acute anuric renal failure. *Am J Med Sci* 302:28–30
39. Laxenaire MC, Charpentier C, Feldman L (1994) Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. *Ann Fr Anesth Reanim* 13:301–310
40. Mailloux L, Swartz CD, Capizzi R, Kim KE, Onesti G, Ramirez O, Brest AN (1967) Acute renal failure after administration of low-molecular weight dextran. *N Engl J Med* 277:1113–1118
41. Messmer KFW (1987) The use of plasma substitutes with special attention to their side-effects. *World J Surg* 11:69–74
42. Fliser D, Zurbruggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E (1999) Coadministration of albumin and furosemide in patients with the nephrotic syndrome. *Kidney Int* 55:629–634
43. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y (1987) Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. *Kidney Int* 32 (2):198–203
44. Wiedermann CJ, Dunzendorfer S, Gaioni LU, Zaraca F, Joannidis M (2010) Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. *Crit Care* 14:R191
45. Wiedermann CJ, Joannidis M (2015) Nephroprotective potential of human albumin infusion: a narrative review. *Gastroenterol Res Pract* 2015:912839
46. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators (2004) A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 350:2247–2256
47. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 345:1368–1377
48. Serrano AB, Candelato-Toha AM, Zamora J, Vera J, Muriel A, Del Rey JM, Liano F (2016) Preoperative hydration with 0.9% normal saline to prevent acute kidney injury after major elective open abdominal surgery: a randomised controlled trial. *Eur J Anaesthesiol* 33:436–443
49. Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettila V, Aaen A, Lodahl D, Berthelsen RE, Christensen H, Madsen MB, Winkel P, Wetterslev J, Perner A, CLASSIC Trial Group, Scandinavian Critical Care Trials Group (2016) Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel-group, multicentre feasibility trial. *Intensive Care Med* 42:1695–1705
50. Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M (2012) Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. *JAMA* 308:1566–1572
51. Shaw AD, Raghunathan K, Peyerl FW, Munson SH, Paluszkiwicz SM, Schermer CR (2014) Association between intravenous chloride load during resuscitation and in-hospital mortality among patients with SIRS. *Intensive Care Med* 40:1897–1905
52. Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). *Crit Care* 17:204
53. Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, McGuinness S, Mehrtens J, Myburgh J, Psirides A, Reddy S, Bellomo R (2015) Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. *JAMA* 314:1701–1710
54. Joannidis M, Forni LG (2016) Acute kidney injury: buffered crystalloids or saline in the ICU—a SPLIT decision. *Nat Rev Nephrol* 12:6–8
55. Semler MW, Wanderer JP, Ehrenfeld JM, Stollings JL, Self WH, Siew ED, Wang L, Byrne DW, Shaw AD, Bernard GR, Rice TW, SALT Investigators and the Pragmatic Critical Care Research Group (2017) Balanced crystalloids versus saline in the intensive care unit: the SALT randomized trial. *Am J Respir Crit Care Med*. doi: 10.1164/rccm.201607-1345OC
56. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Reade MC, Bagshaw SM, Seevanayagam N, Seevanayagam S, Doolan L, Buxton B, Dragun D (2009) Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot double-blind, randomized controlled trial. *Crit Care Med* 37:39–47
57. McGuinness SP, Parke RL, Bellomo R, Van Haren FM, Bailey M (2013) Sodium bicarbonate infusion to reduce cardiac surgery-associated acute kidney injury: a phase II multicenter double-blind randomized controlled trial. *Crit Care Med* 41:1599–1607
58. Kristeller JL, Zavorsky GS, Prior JE, Keating DA, Brady MA, Romaldini TA, Hickman TL, Stahl RF (2013) Lack of effectiveness of sodium bicarbonate in preventing kidney injury in patients undergoing cardiac surgery: a randomized controlled trial. *Pharmacotherapy* 33:710–717
59. Haase M, Haase-Fielitz A, Plass M, Kuppe H, Hetzer R, Hannon C, Murray PT, Bailey MJ, Bellomo R, Bagshaw SM (2013) Prophylactic perioperative sodium bicarbonate to prevent acute kidney injury following open heart surgery: a multicenter double-blinded randomized controlled trial. *PLoS Med* 10:e1001426
60. Tie HT, Luo MZ, Luo MJ, Zhang M, Wu QC, Wan JY (2014) Sodium bicarbonate in the prevention of cardiac surgery-associated acute kidney injury: a systematic review and meta-analysis. *Crit Care* 18:517
61. Tian ML, Hu Y, Yuan J, Zha Y (2015) Efficacy and safety of perioperative sodium bicarbonate therapy for cardiac surgery-associated acute kidney injury: a meta-analysis. *J Cardiovasc Pharmacol* 65:130–136
62. Kim JH, Kim HJ, Kim JY, Ahn H, Ahn IM, Choe WJ, Lim CH (2015) Meta-analysis of sodium bicarbonate therapy for prevention of cardiac surgery-associated acute kidney injury. *J Cardiothorac Vasc Anesth* 29:1248–1256
63. Bailey M, McGuinness S, Haase M, Haase-Fielitz A, Parke R, Hodgson CL, Forbes A, Bagshaw SM, Bellomo R (2015) Sodium bicarbonate and renal function after cardiac surgery: a prospectively planned individual patient meta-analysis. *Anesthesiology* 122:294–306
64. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA, CHEST Investigators, Australian and New Zealand Intensive Care Society Clinical Trials Group (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. *N Engl J Med* 367:1901–1911
65. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Opper M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K, German Competence Network Sepsis (SepNet) (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 358:125–139
66. Perner A, Haase N, Guttorfmsen AB, Tenhunen J, Klemenzson G, Aneman A, Madsen KR, Moller MH, Elkjaer JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Soe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjaeldgaard AL, Fabritius ML, Mondrup F, Pott FC, Moller TP, Winkel P, Wetterslev J, 6S Trial Group, Scandinavian Critical Care Trials Group (2012) Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med* 367:124–134
67. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S, CHEST Management Committee (2013) Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review

- of effects on mortality and treatment with renal replacement therapy. *Intensive Care Med* 39:558–568
68. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA (2013) Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. *JAMA* 309:678–688
  69. Rochwerg B, Alhazzani W, Gibson A, Ribic CM, Sindi A, Heels-Ansell D, Thabane L, Fox-Robichaud A, Mbuagbaw L, Szczeklik W, Alshamsi F, Altayyar S, Ip W, Li G, Wang M, Wludarczyk A, Zhou Q, Annane D, Cook DJ, Jaeschke R, Guyatt GH (2015) Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis. *Intensive Care Med* 41:1561–1571
  70. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J (2013) Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. *BMJ* 346:f839
  71. Mutter TC, Ruth CA, Dart AB (2013) Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. *Cochrane Database Syst Rev* 7:CD007594. doi:10.1002/14651858.CD007594.pub3.
  72. Reinhart K, Perner A, Sprung CL, Jaeschke R, Schortgen F, Johan Groeneveld AB, Beale R, Hartog CS, European Society of Intensive Care Medicine (2012) Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. *Intensive Care Med* 38:368–383
  73. Moeller C, Fleischmann C, Thomas-Rueddel D, Vlasakov V, Rochwerg B, Theurer P, Gattinoni L, Reinhart K, Hartog CS (2016) How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin. *J Crit Care* 35:75–83
  74. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, Fanizza C, Caspani L, Faenza S, Grasselli G, Iapichino G, Antonelli M, Parrini V, Fiore G, Latini R, Gattinoni L, ALBIOS Study Investigators (2014) Albumin replacement in patients with severe sepsis or septic shock. *N Engl J Med* 370:1412–1421
  75. Dubois MJ, Orellana-Jimenez C, Melot C, De Backer D, Berre J, Leeman M, Brimiouille S, Appoloni O, Creteur J, Vincent JL (2006) Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. *Crit Care Med* 34:2536–2540
  76. Wiedermann CJ, Joannidis M (2014) Albumin replacement in severe sepsis or septic shock. *N Engl J Med* 371:83
  77. Patel A, Laffan MA, Waheed U, Brett SJ (2014) Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. *BMJ* 349:g4561
  78. Lee EH, Kim WJ, Kim JY, Chin JH, Choi DK, Sim JY, Choo SJ, Chung CH, Lee JW, Choi IC (2016) Effect of exogenous albumin on the incidence of postoperative acute kidney injury in patients undergoing off-pump coronary artery bypass surgery with a preoperative albumin level of less than 4.0 g/dl. *Anesthesiology* 124:1001–1011
  79. Pannu N, Nadim MK (2008) An overview of drug-induced acute kidney injury. *Crit Care Med* 36:5216–223
  80. Perazella MA, Luciano RL (2015) Review of select causes of drug-induced AKI. *Expert Rev Clin Pharmacol* 8(4):367–371
  81. Branch RA (1988) Prevention of amphotericin-B induced renal impairment. A review on the use of sodium supplementation. *Arch Intern Med* 148:2389–2394
  82. Cheung TW, Jayaweera DT, Pearce D, Benson P, Nahass R, Olson C, Wool GM (2000) Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. *Int J STD AIDS* 11:640–647
  83. Safrin S, Cherrington J, Jaffe HS (1999) Cidofovir. Review of current and potential clinical uses. *Adv Exp Med Biol* 458:111–120
  84. Perazella MA (1999) Crystal-induced acute renal failure. *Am J Med* 106:459–465
  85. Solomon R, Werner C, Mann D, D'Elia J, Silva P (1994) Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. *N Engl J Med* 331:1416–1420
  86. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H (2002) Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med* 162:329–336
  87. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersini RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP (2004) Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA* 291:2328–2334
  88. Ozcan EE, Guneri S, Akdeniz B, Akyildiz IZ, Senaslan O, Baris N, Aslan O, Badak O (2007) Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. *Am Heart J* 154:539–544
  89. Masuda M, Yamada T, Mine T, Morita T, Tamaki S, Tsukamoto Y, Okuda K, Iwasaki Y, Hori M, Fukunami M (2007) Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. *Am J Cardiol* 100:781–786
  90. Briguori C, Airolidi F, D'Andrea D, Bonizzoni E, Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, Ricciardelli B, Colombo A (2007) Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAT): a randomized comparison of 3 preventive strategies. *Circulation* 115:1211–1217
  91. Nijssen EC, Renneberg RJ, Nelemans PJ, Essers BA, Janssen MM, Vermeeren MA, Ommen VV, Wildberger JE (2017) Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. *Lancet* 389:1312–1322
  92. Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. *AJR Am J Roentgenol* 191:376–382
  93. Wilhelm-Leen E, Montez-Rath ME, Chertow G (2017) Estimating the risk of radiocontrast-associated nephropathy. *J Am Soc Nephrol* 28:653–659
  94. Hoste EA, Doom S, De Waele J, Delrue LJ, Defreyne L, Benoit DD, Decruyenaere J (2011) Epidemiology of contrast-associated acute kidney injury in ICU patients: a retrospective cohort analysis. *Intensive Care Med* 37:1921–1931
  95. Cely CM, Schein RM, Quartin AA (2012) Risk of contrast induced nephropathy in the critically ill: a prospective, case matched study. *Crit Care* 16:R67
  96. Ehrmann S, Badin J, Savath L, Pajot O, Garot D, Pham T, Capdevila X, Perrotin D, Lakkhal K (2013) Acute kidney injury in the critically ill: is iodinated contrast medium really harmful? *Crit Care Med* 41:1017–1026
  97. McDonald JS, McDonald RJ, Williamson EE, Kallmes DF, Kashani K (2017) Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. *Intensive Care Med*. doi:10.1007/s00134-017-4699-y
  98. Hinson JS, Ehmann MR, Fine DM, Fishman EK, Toerper MF, Rothman RE, Klein EY (2017) Risk of acute kidney injury after intravenous contrast media administration. *Ann Emerg Med* 69:577–586.e4
  99. Ehrmann S, Quartin A, Hobbs BP, Robert-Edan V, Cely C, Bell C, Lyons G, Pham T, Schein R, Geng Y, Lakkhal K, Ng CS (2017) Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. *Intensive Care Med*. doi:10.1007/s00134-017-4700-9
  100. Valette X, Desmeulles I, Savary B, Masson R, Seguin A, Sauneuf B, Brunet J, Verrier P, Pottier V, Orabona M, Samba D, Viquesnel G, Lermuzeaux M, Hazera P, Duthiel JJ, Hanouz JL, Parienti JJ, du Cheyron D (2017) Sodium bicarbonate versus sodium chloride for preventing contrast-associated acute kidney injury in critically ill patients: a randomized controlled trial. *Crit Care Med* 45:637–644
  101. Liu Y, Li H, Chen S, Chen J, Tan N, Zhou Y, Liu Y, Ye P, Ran P, Duan C, Chen P (2016) Excessively high hydration volume may not be associated with decreased risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with renal insufficiency. *J Am Heart Assoc*. doi:10.1161/JAHA.115.003171
  102. Bagshaw SM, Delaney A, Jones D, Ronco C, Bellomo R (2007) Diuretics in the management of acute kidney injury: a multinational survey. *Contrib Nephrol* 156:236–249

103. Bayati A, Nygren K, Kallskog O, Wolgast M (1990) The effect of loop diuretics on the long-term outcome of post-ischaemic acute renal failure in the rat. *Acta Physiol Scand* 139:271–279
104. Heyman SN, Rosen S, Epstein FH, Spokes K, Brezis ML (1994) Loop diuretics reduce hypoxic damage to proximal tubules of the isolated perfused rat kidney. *Kidney Int* 45:981–985
105. Kramer HJ, Schuurmann J, Wassermann C, Dusing R (1980) Prostaglandin-independent protection by furosemide from oliguric ischemic renal failure in conscious rats. *Kidney Int* 17:455–464
106. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D (2013) Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. *Crit Care* 17:R278
107. Chen KP, Cavender S, Lee J, Feng M, Mark RG, Celi LA, Mukamal KJ, Danziger J (2016) Peripheral edema, central venous pressure, and risk of AKI in critical illness. *Clinic J Am Soc Nephrol* 11:602–608
108. Wu YF, Zheng YP, Zhang N, Liu H, Zheng QX, Yang FT, Wu YF (2015) Study on the correlation between the changes in intra-abdominal pressure and renal functional in the patients with abdominal compartment syndrome. *Eur Rev Med Pharmacol Sci* 19:3682–3687
109. Cordemans C, De Laet I, Van Regenmortel N, Schoonheydt K, Dits H, Huber W, Malbrain ML (2012) Fluid management in critically ill patients: the role of extravascular lung water, abdominal hypertension, capillary leak, and fluid balance. *Ann Intensive Care* 2:S1
110. Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG (2013) Development and standardization of a furosemide stress test to predict the severity of acute kidney injury. *Crit Care* 17:R207
111. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL (2006) Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 354:2564–2575
112. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M (2000) Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. *J Am Soc Nephrol* 11:97–104
113. Brown CB, Ogg CS, Cameron JS (1981) High dose frusemide in acute renal failure: a controlled trial. *Clin Nephrol* 15:90–96
114. Ho KM, Power BM (2010) Benefits and risks of furosemide in acute kidney injury. *Anaesthesia* 65:283–293
115. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM, NHLBI Heart Failure Clinical Research Network (2011) Diuretic strategies in patients with acute decompensated heart failure. *N Engl J Med* 364:797–805
116. Cotter G, Weissgarten J, Metzker E, Moshkovitz Y, Litinski I, Tavori U, Perry C, Zaidenstein R, Golik A (1997) Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. *Clin Pharmacol Ther* 62:187–193
117. Hager B, Betschart M, Krapf R (1996) Effect of postoperative intravenous loop diuretic on renal function after major surgery. *Schweiz Med Wochenschr* 126:666–673
118. van der Voort PHJ, Boerma EC, Koopmans M, Zandberg M, de Ruyter J, Gerritsen RT, Egbers PH, Kingma WP, Kuiper MA (2009) Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. *Crit Care Med* 37:533–538
119. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD (1994) Intravenous immunoglobulin-induced osmotic nephrosis. *Arch Intern Med* 154:1985–1987
120. Shilliday IR, Quinn KJ, Allison ME (1997) Loop diuretics in the management of acute renal failure: a prospective, double-blind, placebo-controlled, randomized study. *Nephrol Dial Transplant* 12:2592–2596
121. Sirivella S, Gielchinsky I, Parsonnet V (2000) Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. *Ann Thorac Surg* 69:501–506
122. Ho KM, Sheridan DJ (2006) Meta-analysis of frusemide to prevent or treat acute renal failure. *BMJ* 333:420
123. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R (2007) Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. *Crit Care Resusc* 9:60–68
124. Sampath S, Moran JL, Graham PL, Rockliff S, Bersten AD, Abrams KR (2007) The efficacy of loop diuretics in acute renal failure: assessment using Bayesian evidence synthesis techniques. *Crit Care Med* 35:2516–2524
125. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Herve F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P, Investigators S (2014) High versus low blood-pressure target in patients with septic shock. *N Engl J Med* 370:1583–1593
126. Qureshi AI, Palesch YY, Suarez JJ (2016) Intensive blood-pressure lowering in cerebral hemorrhage. *N Engl J Med* 375:e48
127. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, SOAP II Investigators (2010) Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 362:779–789
128. Serpa Neto A, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Esposito DC, Damasceno MC, Russell JA (2012) Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. *Crit Care* 16:R154
129. Bragadottir G, Redfors B, Nygren A, Sellgren J, Ricksten SE (2009) Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients. *Acta Anaesthesiol Scand* 53:1052–1059
130. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, Cook DJ, Presneill JJ, Ayers D, VASST Investigators (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 358:877–887
131. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, Holmes CL, Hebert PC, Cooper DJ, Mehta S, Granton JT, Cook DJ, Presneill JJ (2010) The effects of vasopressin on acute kidney injury in septic shock. *Intensive Care Med* 36:83–91
132. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, VANISH Investigators (2016) Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. *JAMA* 316:509–518
133. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, Melo RR, Sundin MR, Grande SM, Gaiotto FA, Pomerantzeff PM, Dallan LO, Franco RA, Nakamura RE, Lisboa LA, de Almeida JP, Gerent AM, Souza DH, Gaiane MA, Fukushima JT, Park CL, Zambolim C, Rocha Ferreira GS, Strabelli TM, Fernandes FL, Camara L, Zeferino S, Santos VG, Piccioni MA, Jatene FB, Costa Auler Jo Jr, Filho RK (2017) Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. *Anesthesiology* 126:85–93
134. Ramaswamy D, Corrigan G, Polhemus C, Boothroyd D, Scandling J, Sommer FG, Alfrey E, Higgins J, Deen WM, Olshen R, Myers BD (2002) Maintenance and recovery stages of posts ischemic acute renal failure in humans. *Am J Physiol Renal Physiol* 282:F271–F280
135. Conger J, Robinette J, Villar A, Raij L, Shultz P (1995) Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in posts ischemic acute renal failure in rats. *J Clin Invest* 96:631–638
136. Wan L, Bagshaw SM, Langenberg C, Saotome T, May C, Bellomo R (2008) Pathophysiology of septic acute kidney injury: what do we really know? *Crit Care Med* 36:S198–S203
137. Ishikawa K, May CN, Gobe G, Langenberg C, Bellomo R (2010) Pathophysiology of septic acute kidney injury: a different view of tubular injury. *Contrib Nephrol* 165:18–27
138. Legrand M, Bezemer R, Kandil A, Demirci C, Payen D, Ince C (2011) The role of renal hypoperfusion in development of renal microcirculatory dysfunction in endotoxemic rats. *Intensive Care Med* 37:1534–1542
139. Molitoris BA, Sutton TA (2004) Endothelial injury and dysfunction: role in the extension phase of acute renal failure. *Kidney Int* 66:496–499

140. Lauschke A, Teichgraber UKM, Frei U, Eckardt KU (2006) 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. *Kidney Int* 69:1669–1674
141. Friedrich JO, Adhikari N, Herridge MS, Beyene J (2005) Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med* 142:510–524
142. Karthik S, Lisbon A (2006) Low-dose dopamine in the intensive care unit. *Semin Dial* 19:465–471
143. Holmes CL, Walley KR (2003) Bad medicine: low-dose dopamine in the ICU. *Chest* 123:1266–1275
144. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG, Ranucci M, Zangrillo A (2007) Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Am J Kidney Dis* 49:56–68
145. Zangrillo A, Biondi-Zoccai GG, Frati E, Covello RD, Cabrini L, Guarracino F, Ruggeri L, Bove T, Bignami E, Landoni G (2012) Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. *J Cardiothorac Vasc Anesth* 26:407–413
146. Gillies MA, Kakar V, Parker RJ, Honore PM, Ostermann M (2015) Fenoldopam to prevent acute kidney injury after major surgery—a systematic review and meta-analysis. *Crit Care* 19:449
147. Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal CE, Cariello C, Faita L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabro MG, Bellomo R, Landoni G (2014) Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. *JAMA* 312:2244–2253
148. Sward K, Valson F, Ricksten SE (2001) Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. *Acta Anaesthesiol Scand* 45:536–542
149. Sward K, Valsson F, Sellgren J, Ricksten SE (2005) Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. *Intensive Care Med* 31:79–85
150. Houben AJ, van der Zander K, de Leeuw PW (2005) Vascular and renal actions of brain natriuretic peptide in man: physiology and pharmacology. *Fundam Clin Pharmacol* 19:411–419
151. Kuhn M (2012) Endothelial effects of atrial and B-type natriuretic peptides. *Br J Pharmacol* 166:522–531
152. Mitaka C, Kudo T, Haraguchi G, Tomita M (2011) Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. *Crit Care* 15:R258
153. Patel NN, Rogers CA, Angelini GD, Murphy GJ (2011) Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: a systematic review. *Heart Fail Rev* 16:553–567
154. Nigwekar SU, Navaneethan SD, Parikh CR, Hix JK (2009) Atrial natriuretic peptide for preventing and treating acute kidney injury. *Cochrane Database Syst Rev* CD006028. doi:10.1002/14651858.CD006028.pub2
155. Sezai A, Nakata K, Iida M, Yoshitake I, Wakui S, Hata H, Shiono M (2013) Results of low-dose carperitide infusion in high-risk patients undergoing coronary artery bypass grafting. *Ann Thorac Surg* 96:119–126
156. Mori Y, Kamada T, Ochiai R (2014) Reduction in the incidence of acute kidney injury after aortic arch surgery with low-dose atrial natriuretic peptide: a randomised controlled trial. *Eur J Anaesthesiol* 31:381–387
157. Xiong B, Wang C, Yao Y, Huang Y, Tan J, Cao Y, Zou Y, Huang J (2015) The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 10:e0131326
158. Papp Z, Edes I, Fruhwald S, De Hert SG, Salmenpera M, Leppikangas H, Mebazaa A, Landoni G, Grossini E, Caimmi P, Morelli A, Guarracino F, Schwinger RH, Meyer S, Algotsson L, Wikstrom BG, Jorgensen K, Filipatos G, Parissis JT, Gonzalez MJ, Parkhomenko A, Yilmaz MB, Kivikko M, Pollesello P, Follath F (2012) Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. *Int J Cardiol* 159:82–87
159. Hasslacher J, Bujuklic K, Bertocchi C, Kountchev J, Bellmann R, Dunzendorfer S, Joannidis M (2011) Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. *Crit Care* 15:R166
160. Bove T, Matteazzi A, Belletti A, Paternoster G, Saleh O, Taddeo D, Dossi R, Greco T, Bradic N, Husedzinovic I, Nigro Neto C, Lomivorotov VV, Calabro MG (2015) Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Heart Lung Vessel* 7:35–46
161. Zhou C, Gong J, Chen D, Wang W, Liu M, Liu B (2016) Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. *Am J Kidney Dis* 67:408–416
162. Gordon AC, Perkins GD, Singer M, McAuley DF, Orme RM, Santhakumaran S, Mason AJ, Cross M, Al-Beidh F, Best-Lane J, Brealey D, Nutt CL, McNamee JJ, Reschreiter H, Breen A, Liu KD, Ashby D (2016) Levosimendan for the prevention of acute organ dysfunction in sepsis. *N Engl J Med* 375:1638–1648
163. Mehta RH, Leimberger JD, van Diepen S, Meza J, Wang A, Jankowich R, Harrison RW, Hay D, Fremes S, Duncan A, Soltesz EG, Luber J, Park S, Argenziano M, Murphy E, Marcel R, Kalavrouziotis D, Nagpal D, Bozinovski J, Toller W, Heringlake M, Goodman SG, Levy JH, Harrington K, Anstrom KJ, Alexander JH, LEVO-CTS Investigators (2017) Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. *N Engl J Med*. doi:10.1056/NEJMoa1616218
164. Landoni G, Lomivorotov VV, Alvaro G, Lobreglio R, Pisano A, Guaracino F, Calabro MG, Grigoryev EV, Likhvantsev VV, Salgado-Filho MF, Bianchi A, Pasyuga VV, Baiocchi M, Pappalardo F, Monaco F, Boboshko VA, Abubakirov MN, Amantea B, Lembo R, Brazzi L, Verniero L, Bertini P, Scandroglio AM, Bove T, Belletti A, Michienzi MG, Shukevich DL, Zabelina TS, Bellomo R, Zangrillo A, CHEETAH Study Group (2017) Levosimendan for hemodynamic support after cardiac surgery. *N Engl J Med*. doi:10.1056/NEJMoa1616325
165. Luo C, Yuan D, Li X, Yao W, Luo G, Chi X, Li H, Irwin MG, Xia Z, Hei Z (2015) Propofol attenuated acute kidney injury after orthotopic liver transplantation via inhibiting gap junction composed of connexin 32. *Anesthesiology* 122:72–86
166. Hsing CH, Chou W, Wang JJ, Chen HW, Yeh CH (2011) Propofol increases bone morphogenetic protein-7 and decreases oxidative stress in sepsis-induced acute kidney injury. *Nephrol Dial Transplant* 26:1162–1172
167. Villela NR, Nascimento Junior P, Carvalho LR, Teixeira A (2005) Effects of dexmedetomidine on renal system and on vasopressin plasma levels. Experimental study in dogs. *Rev Bras Anesthesiol* 55:429–440
168. Billings FT, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT (2008) alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. *Am J Physiol Renal Physiol* 295:F741–748
169. Hsing CH, Lin CF, So E, Sun DP, Chen TC, Li CF, Yeh CH (2012) alpha2-Adrenoceptor agonist dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5. *Am J Physiol Renal Physiol* 303:F1443–F1453
170. Tan F, Chen Y, Yuan D, Gong C, Li X, Zhou S (2015) Dexmedetomidine protects against acute kidney injury through downregulating inflammatory reactions in endotoxemia rats. *Biomed Rep* 3:365–370
171. Yao H, Chi X, Jin Y, Wang Y, Huang P, Wu S, Xia Z, Cai J (2015) Dexmedetomidine inhibits TLR4/NF-kappaB activation and reduces acute kidney injury after orthotopic autologous liver transplantation in rats. *Sci Rep* 5:16849
172. Reade MC, Finfer S (2014) Sedation and delirium in the intensive care unit. *N Engl J Med* 370:444–454
173. Mirrahimov AE, Voore P, Halysky O, Khan M, Ali AM (2015) Propofol infusion syndrome in adults: a clinical update. *Crit Care Res Pract* 2015:260385
174. Krajcova A, Waldauf P, Andel M, Duska F (2015) Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. *Crit Care* 19:398
175. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ (2001) Long-term propofol infusion and cardiac failure in adult head-injured patients. *Lancet* 357:117–118
176. Leite TT, Macedo E, Martins Ida S, Neves FM, Liborio AB (2015) Renal outcomes in critically ill patients receiving propofol or midazolam. *Clin J Am Soc Nephrol* 10:1937–1945
177. Yoo YC, Shim JK, Song Y, Yang SY, Kwak YL (2014) Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. *Kidney Int* 86:414–422



178. Menting TP, Wever KE, Ozdemir-van Brunschot DM, Van der Vliet DJ, Rovers MM, Warle MC (2017) Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury. *Cochrane Database Syst Rev* 3:Cd010777
179. Pichot C, Longrois D, Ghignone M, Quintin L (2012) Dexmedetomidine and clonidine: a review of their pharmacodynamics to define their role for sedation in intensive care patients. *Ann Fr Anesth Reanim* 31:876–896
180. Leino K, Hynynen M, Jalonen J, Salmenpera M, Scheinin H, Aantaa R, Dexmedetomidine in Cardiac Surgery Study Group (2011) Renal effects of dexmedetomidine during coronary artery bypass surgery: a randomized placebo-controlled study. *BMC Anesthesiol* 11:9
181. Ji F, Li Z, Young JN, Yeranossian A, Liu H (2013) Post-bypass dexmedetomidine use and postoperative acute kidney injury in patients undergoing cardiac surgery with cardiopulmonary bypass. *PLoS One* 8:e77446
182. Moon T, Tsai JY, Vachhani S, Peng SP, Feng L, Vaporciyan AA, Cata JP (2016) The use of intraoperative dexmedetomidine is not associated with a reduction in acute kidney injury after lung cancer surgery. *J Cardiothorac Vasc Anesth* 30:51–55
183. Balkanay OO, Goksefend D, Omeroglu SN, Ipek G (2015) The dose-related effects of dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery bypass grafting: a randomized, triple-blind, placebo-controlled study. *Interact Cardiovasc Thorac Surg* 20:209–214
184. Cho JS, Shim JK, Soh S, Kim MK, Kwak YL (2016) Perioperative dexmedetomidine reduces the incidence and severity of acute kidney injury following valvular heart surgery. *Kidney Int* 89:693–700
185. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE (2002) Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. *J Clin Endocrinol Metab* 87:978–982
186. Krinsley JS (2003) Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc* 78:1471–1478
187. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in critically ill patients. *N Engl J Med* 345:1359–1367
188. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R (2006) Intensive insulin therapy in the medical ICU. *N Engl J Med* 354:449–461
189. Schetz M, Vanhorebeek I, Wouters PJ, Wilmer A, van den Berghe G (2008) Tight blood glucose control is renoprotective in critically ill patients. *J Am Soc Nephrol* 19: 571–578
190. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, Syed SJ, Giridhar HR, Rishu AH, Al-Daker MO, Kahoul SH, Britts RJ, Sakkijha MH (2008) Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. *Crit Care Med* 36:3190–3197
191. Investigators N-SS, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ (2009) Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 360:1283–1297
192. Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, Iapichino G, Lervere X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chiolero R (2009) A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med* 35:1738–1748
193. Arabi YM, Tamim HM, Dhar GS, Al-Dawood A, Al-Sultan M, Sakkijha MH, Kahoul SH, Brits R (2011) Permissive underfeeding and intensive insulin therapy in critically ill patients: a randomized controlled trial. *Am J Clin Nutr* 93:569–577
194. De La Rosa GC, Donado JH, Restrepo AH, Quintero AM, Gonzalez LG, Saldarriaga NE, Bedoya M, Toro JM, Velasquez JB, Valencia JC, Arango CM, Aleman PH, Vasquez EM, Chavarriaga JC, Yepes A, Pulido W, Cadavid CA (2008) Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. *Crit Care* 12:R120
195. Van den Berghe G, Schetz M, Vlasselaers D, Hermans G, Wilmer A, Bouillon R, Mesotten D (2009) Clinical review: intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? *J Clin Endocrinol Metab* 94:3163–3170
196. Ling Y, Li X, Gao X (2012) Intensive versus conventional glucose control in critically ill patients: a meta-analysis of randomized controlled trials. *Eur J Intern Med* 23:564–574
197. Dickerson RN, Hamilton LA, Connor KA, Maish GO 3rd, Croce MA, Minard G, Brown RO (2011) Increased hypoglycemia associated with renal failure during continuous intravenous insulin infusion and specialized nutritional support. *Nutrition* 27:766–772
198. Kosiborod M, Inzucchi SE, Goyal A, Krumholz HM, Masoudi FA, Xiao L, Spertus JA (2009) Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *JAMA* 301:1556–1564
199. Mowery NT, Guillaumondegui OD, Gunter OL, Diaz JJ Jr, Collier BR, Dossert LA, Dortch MJ, May AK (2010) Severe hypoglycemia while on intensive insulin therapy is not an independent predictor of death after trauma. *J Trauma* 68:342–347
200. NICE-SUGAR Study Investigators, Finfer S, Liu B, Chittock DR, Norton R, Myburgh JA, McArthur C, Mitchell I, Foster D, Dhingra V, Henderson WR, Ronco JJ, Bellomo R, Cook D, McDonald E, Dodek P, Hebert PC, Heyland DK, Robinson BG (2012) Hypoglycemia and risk of death in critically ill patients. *N Engl J Med* 367:1108–1118
201. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, Inzucchi SE, Ismail-Beigi F, Kirkman MS, Umpierrez GE (2009) American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *EndocrPract* 15:353–369
202. van den Berghe G (2013) What's new in glucose control in the ICU? *Intensive Care Med* 39:823–825
203. Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, Tijssen JG, Numan SC, Kalkman CJ, van Dijk D, Dexamethasone for Cardiac Surgery Study Group (2012) Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. *JAMA* 308:1761–1767
204. Jacob KA, Leaf DE, Dieleman JM, van Dijk D, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, de Lange F, Boer C, Kluijn J, Waikar SS, Dexamethasone for Cardiac Surgery Study Group (2015) Intraoperative high-dose dexamethasone and severe AKI after cardiac surgery. *J Am Soc Nephrol* 26:2947–2951
205. Whitlock RP, Devereaux PJ, Teoh KH, Lamy A, Vincent J, Pogue J, Paparella D, Sessler DI, Karthikeyan G, Villar JC, Zuo Y, Avezum A, Quantz M, Tagarakis GI, Shah PJ, Abbasi SH, Zheng H, Pettit S, Chrolavicius S, Yusuf S (2015) Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. *Lancet* 386:1243–1253
206. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY (2009) Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. *Am J Nephrol* 30:253–260
207. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P (2012) Epoetin administered after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. *BMC Nephrol* 13:132
208. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL (2011) Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. *Anesthesiology* 115:929–937
209. Kim JH, Shim JK, Song JW, Song Y, Kim HB, Kwak YL (2013) Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety. *Crit Care* 17:R254
210. Tasanarong A, Duangchana S, Sumransurp S, Homwises B, Satdhabudha O (2013) Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. *BMC Nephrol* 14:136
211. Tie HT, Luo MZ, Lin D, Zhang M, Wan JY, Wu QC (2015) Erythropoietin administration for prevention of cardiac surgery-associated acute

- kidney injury: a meta-analysis of randomized controlled trials. *Eur J Cardiothorac Surg* 48:32–39
212. Penny-Dimri JC, Cochrane AD, Perry LA, Smith JA (2016) Characterising the role of perioperative erythropoietin for preventing acute kidney injury after cardiac surgery: systematic review and meta-analysis. *Heart Lung Circ* 25:1067–1076
  213. Dardashti A, Ederoth P, Algotsson L, Bronden B, Grins E, Larsson M, Nozohoor S, Zinko G, Bjursten H (2014) Erythropoietin and protection of renal function in cardiac surgery (the EPRICS Trial). *Anesthesiology* 121:582–590
  214. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrkens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM (2010) Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). *Kidney Int* 77:1020–1030
  215. Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T, EPO Critical Care Trials Group (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. *JAMA* 288:2827–2835
  216. Zhao C, Lin Z, Luo Q, Xia X, Yu X, Huang F (2015) Efficacy and safety of erythropoietin to prevent acute kidney injury in patients with critical illness or perioperative care: a systematic review and meta-analysis of randomized controlled trials. *J Cardiovasc Pharmacol* 65:593–600
  217. Kim JE, Song SW, Kim JY, Lee HJ, Chung KH, Shim YH (2016) Effect of a single bolus of erythropoietin on renoprotection in patients undergoing thoracic aortic surgery with moderate hypothermic circulatory arrest. *Ann Thorac Surg* 101:690–696
  218. Shema-Didi L, Kristal B, Eizenberg S, Marzuq N, Sussan M, Feldman-Idov Y, Ofir P, Atar S (2016) Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: a randomized controlled trial. *Nephrology (Carlton)* 21:295–300
  219. Pons M, Plante I, LeBrun M, Gourde P, Simard M, Grenier L, Thibault L, Labrecque G, Beauchamp D (2003) Protein-rich diet attenuates cyclosporin a-induced renal tubular damage in rats. *J Ren Nutr* 13:84–92
  220. Roberts PR, Black KW, Zaloga GP (1997) Enteral feeding improves outcome and protects against glycerol-induced acute renal failure in the rat. *Am J Respir Crit Care Med* 156:1265–1269
  221. Mouser JF, Hak EB, Kuhl DA, Dickerson RN, Gaber LW, Hak LJ (1997) Recovery from ischemic acute renal failure is improved with enteral compared with parenteral nutrition. *Crit Care Med* 25:1748–1754
  222. Zager RA (1987) Amino acid hyperalimentation in acute renal failure: a potential therapeutic paradox. *Kidney Int Suppl* 22:572–575
  223. Heyland DK, Elke G, Cook D, Berger MM, Wischmeyer PE, Albert M, Muscedere J, Jones G, Day AG (2015) Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial. *JPEN J Parenter Enteral Nutr* 39:401–409
  224. Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, Chu T, Forrer F, Muller C, de Jong M, van Ijcken W, IJzermans JN, Hoelijmakers JH, de Bruin RW (2010) Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice. *Aging Cell* 9:40–53
  225. Abel RM, Beck CH Jr, Abbott WM, Ryan JA Jr, Barnett GO, Fischer JE (1973) Improved survival from acute renal failure after treatment with intravenous essential L-amino acids and glucose. Results of a prospective, double-blind study. *N Engl J Med* 288:695–699
  226. Doig GS, Simpson F, Bellomo R, Heighes PT, Sweetman EA, Cheshire D, Pollock C, Davies A, Botha J, Harrigan P, Reade MC (2015) Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. *Intensive Care Med* 41:1197–1208
  227. Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van den Berghe G (2013) Impact of early parenteral nutrition on metabolism and kidney injury. *J Am Soc Nephrol* 24:995–1005
  228. Al-Dorzi HM, Albarrak A, Ferwana M, Murad MH, Arabi YM (2016) Lower versus higher dose of enteral caloric intake in adult critically ill patients: a systematic review and meta-analysis. *Crit Care* 20:358
  229. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL (2007) A meta-analysis of N-acetylcysteine in contrast-induced nephropathy: unsupervised clustering to resolve heterogeneity. *BMC Med* 5:32
  230. Zagler A, Azadpour M, Mercado C, Hennekens CH (2006) N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. *Am Heart J* 151:140–145
  231. Duong MH, MacKenzie TA, Malenka DJ (2005) N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. *Catheter Cardiovasc Interv* 64:471–479
  232. Pannu N, Manns B, Lee H, Tonelli M (2004) Systematic review of the impact of N-acetylcysteine on contrast nephropathy. *Kidney Int* 65:1366–1374
  233. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ (2004) Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. *Am J Kidney Dis* 43:1–9
  234. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC (2008) Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med* 148:284–294
  235. Zhao SJ, Zhong ZS, Qi GX, Tian W (2016) The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: a meta-analysis of randomized controlled trials. *Int J Cardiol* 221:251–259
  236. Wang N, Qian P, Kumar S, Yan TD, Phan K (2016) The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: a systematic review and trial sequential analysis. *Int J Cardiol* 209:319–327
  237. Kang X, Hu DY, Li CB, Ai ZS, Peng A (2015) N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. *Ren Fail* 37(10):297–303
  238. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z (2013) Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. *PLoS One* 8:e55124
  239. ACT Investigators (2011) Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). *Circulation* 124:1250–1259
  240. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, Stitt LW, Heidenheim AP, Myers ML, Moist L (2005) Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. *JAMA* 294:342–350
  241. Macedo E, Abdulkader R, Castro I, Sobrinho AC, Yu L, Vieira JM Jr (2006) Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair—a randomized controlled trial. *Nephrol Dial Transplant* 21:1863–1869
  242. Komisarof JA, Gilkey GM, Peters DM, Koudelka CW, Meyer MM, Smith SM (2007) N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON). *Crit Care Med* 35:435–441
  243. Sisillo E, Ceriani R, Bortone F, Juliano G, Salvi L, Veglia F, Fiorentini C, Marenzi G (2008) N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. *Crit Care Med* 36:81–86
  244. Adabag AS, Ishani A, Koneswaran S, Johnson DJ, Kelly RF, Ward HB, McFalls EO, Bloomfield HE, Chandrashekar Y (2008) Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. *Am Heart J* 155:1143–1149
  245. Song JW, Shim JK, Soh S, Jang J, Kwak YL (2015) Double-blinded, randomized controlled trial of N-acetylcysteine for prevention of acute kidney injury in high risk patients undergoing off-pump coronary artery bypass. *Nephrology (Carlton)* 20:96–102
  246. Wijesundera DN, Beattie WS, Rao V, Granton JT, Chan CT (2007) N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. *Can J Anaesth* 54:872–881
  247. Sandilands EA, Bateman DN (2009) Adverse reactions associated with acetylcysteine. *Clin Toxicol (Phila)* 47:81–88
  248. Molnar Z, Shearer E, Lowe D (1999) N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo-controlled study. *Crit Care Med* 27:1100–1104

249. Peake SL, Moran JL, Leppard PI (1996) *N*-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. *Crit Care Med* 24:1302–1310
250. Angstwurm MW, Schottdorf J, Schopohl J, Gaertner R (1999) Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. *Crit Care Med* 27:1807–1813
251. Mishra V, Baines M, Perry SE, McLaughlin PJ, Carson J, Wenstone R, Shenkin A (2007) Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. *Clin Nutr* 26:41–50
252. Angstwurm MW, Engelmann L, Zimmermann T, Lehmann C, Spes CH, Abel P, Strauss R, Meier-Hellmann A, Insel R, Radke J, Schuttler J, Gartner R (2007) Selenium in Intensive Care (SIC): results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. *Crit Care Med* 35:118–126
253. Bloos F, Trips E, Nierhaus A, Briegel J, Heyland DK, Jaschinski U, Moerer O, Weyland A, Marx G, Grundling M, Kluge S, Kaufmann I, Ott K, Quintel M, Jelschen F, Meybohm P, Rademacher S, Meier-Hellmann A, Utzolino S, Kaisers UX, Putensen C, Elke G, Ragaller M, Gerlach H, Ludewig K, Kiehntopf M, Bogatsch H, Engel C, Brunkhorst FM, Loeffler M, Reinhardt K, for SepNet Critical Care Trials G (2016) Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. *JAMA intern med* 176: 1266–1276
254. Kavalipati N, Shah J, Ramakrishnan A, Vasnawala H (2015) Pleiotropic effects of statins. *Indian J Endocrinol Metab* 19:554–562
255. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, Ding S, Jia S, Shen W, Wang D, Sun L, Qiu J, Wang X, Li Y, Deng J, Li J, Xu K, Xu B, Mehran R, Huo Y (2014) Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. *J Am Coll Cardiol* 63:62–70
256. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F (2014) Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective EFFECT of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). *J Am Coll Cardiol* 63:71–79
257. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, Ricciardelli B, Donnarumma E, Bianco A, Zabatta MA, Troncone G, Colombo A, Briguori C, Condorelli G (2012) Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. *Circulation* 126:3008–3016
258. Shehata M, Hamza M (2015) Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial. *Cardiovasc Ther* 33:35–41
259. Li J, Li Y, Xu B, Jia G, Guo T, Wang D, Xu K, Deng J, Han Y (2016) Short-term rosuvastatin therapy prevents contrast-induced acute kidney injury in female patients with diabetes and chronic kidney disease: a subgroup analysis of the TRACK-D study. *J Thorac Dis* 8:1000–1006
260. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G (2014) The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. *J Thromb Thrombolysis* 38:493–502
261. Lee JM, Park J, Jeon KH, Jung JH, Lee SE, Han JK, Kim HL, Yang HM, Park KW, Kang HJ, Koo BK, Jo SH, Kim HS (2014) Efficacy of short-term high-dose statin pretreatment in prevention of contrast-induced acute kidney injury: updated study-level meta-analysis of 13 randomized controlled trials. *PLoS One* 9:e111397
262. Ukaigwe A, Karmacharya P, Mahmood M, Pathak R, Aryal MR, Jalota L, Donato AA (2014) Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. *Am J Cardiol* 114:1295–1302
263. Singh N, Lee JZ, Huang JJ, Low SW, Howe C, Pandit A, Suryanarayana P, Lee KS (2014) Benefit of statin pretreatment in prevention of contrast-induced nephropathy in different adult patient population: systematic review and meta-analysis. *Open Heart* 1:e000127
264. Marenzi G, Cosentino N, Verba JP, Tedesco CC, Veglia F, Bartorelli AL (2015) A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. *Int J Cardiol* 183:47–53
265. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dorge H, Stamm C, Wassmer G, Wahlers T (2008) Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients. *Eur Heart J* 29:1548–1559
266. Wang J, Gu C, Gao M, Yu W, Yu Y (2015) Preoperative statin therapy and renal outcomes after cardiac surgery: a meta-analysis and meta-regression of 59,771 patients. *Can J Cardiol* 31:1051–1060
267. Lewicki M, Ng I, Schneider AG (2015) HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass. *Cochrane Database Syst Rev* 3:CD010480
268. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ (2016) High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. *JAMA* 315:877–888
269. Park JH, Shim JK, Song JW, Soh S, Kwak YL (2016) Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. *Intensive Care Med* 42:1398–1407
270. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B (2016) Perioperative rosuvastatin in cardiac surgery. *N Engl J Med* 374:1744–1753
271. Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S, Zahn PK, Wolf B, Goebel U, Schwer CI, Rosenberger P, Haeblerle H, Gorlich D, Kellum JA, Meersch M, Renal RI (2015) Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial. *JAMA* 313:2133–2141
272. Zimmerman RF, Ezeanuna PU, Kane JC, Cleland CD, Kempananjappa TJ, Lucas FL, Kramer RS (2011) Ischemic preconditioning at a remote site prevents acute kidney injury in patients following cardiac surgery. *Kidney Int* 80:861–867
273. Kim TK, Min JJ, Cho YJ, Hausenloy DJ, Ahn H, Kim KH, Hwang HY, Hong DM, Jeon Y (2017) Effects of delayed remote ischemic preconditioning on peri-operative myocardial injury in patients undergoing cardiac surgery—a randomized controlled trial. *Int J Cardiol* 227:511–515
274. Meybohm P, Bein B, Brosteanu O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Boning A, Niemann B, Roesner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferner M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schon J, Sander M, Treskatsch S, Smul T, Wolwender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. *N Engl J Med* 373:1397–1407
275. Hong DM, Lee EH, Kim HJ, Min JJ, Chin JH, Choi DK, Bahk JH, Sim JY, Choi IC, Jeon Y (2014) Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial. *Eur Heart J* 35:176–183
276. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM, ERICCA Trial Investigators (2015) Remote ischemic preconditioning and outcomes of cardiac surgery. *N Engl J Med* 373:1408–1417
277. Walsh M, Whitlock R, Garg AX, Legare JF, Duncan AE, Zimmerman R, Miller S, Fremes S, Kieser T, Karthikeyan G, Chan M, Ho A, Nasr V, Vincent J, Ali I, Lavi R, Sessler DJ, Kramer R, Gardner J, Syed S, VanHelder T, Guyatt G, Rao-Melacini P, Thabane L, Devereaux PJ, Remote IMPACT Investigators (2016) Effects of remote ischemic preconditioning in high-risk patients undergoing cardiac surgery (Remote IMPACT): a randomized controlled trial. *CMAJ* 188:329–336
278. Zhang L, Diao Y, Chen G, Tanaka A, Eastwood GM, Bellomo R (2016) Remote ischemic conditioning for kidney protection: a meta-analysis. *J Crit Care* 33:224–232
279. Zhou C, Jeon Y, Meybohm P, Zarbock A, Young PJ, Li L, Hausenloy DJ (2016) Renoprotection by remote ischemic conditioning during elective coronary revascularization: a systematic review and meta-analysis of randomized controlled trials. *Int J Cardiol* 222:295–302
280. Yang Y, Lang XB, Zhang P, Lv R, Wang YF, Chen JH (2014) Remote ischemic preconditioning for prevention of acute kidney injury: a meta-analysis of randomized controlled trials. *Am J Kidney Dis* 64:574–583

281. Li B, Lang X, Cao L, Wang Y, Lu Y, Feng S, Yang Y, Chen J, Jiang H (2017) Effect of remote ischemic preconditioning on postoperative acute kidney injury among patients undergoing cardiac and vascular interventions: a meta-analysis. *J Nephrol* 30:19–33
282. Hu J, Liu S, Jia P, Xu X, Song N, Zhang T, Chen R, Ding X (2016) Protection of remote ischemic preconditioning against acute kidney injury: a systematic review and meta-analysis. *Crit Care* 20:111
283. Pierce B, Bole I, Patel V, Brown DL (2017) Clinical outcomes of remote ischemic preconditioning prior to cardiac surgery: a meta-analysis of randomized controlled trials. *J Am Heart Assoc.* doi:10.1161/JAHA.116.004666
284. Yi B, Chen X, Shi H, Lin T, Lin H, Xu Y, Rong J (2017) Remote ischaemic preconditioning reduces acute kidney injury in adult patients undergoing cardiac surgery with cardiopulmonary bypass: a meta-analysis. *Eur J Cardiothorac Surg* 51:616–623
285. Zhou C, Bulluck H, Fang N, Li L, Hausenloy DJ (2017) Age and surgical complexity impact on renoprotection by remote ischemic preconditioning during adult cardiac surgery: a meta analysis. *Scientific reports* 7:215
286. Zhang Y, Zhang X, Chi D, Wang S, Wei H, Yu H, Li Q, Liu B (2016) Remote ischemic preconditioning for prevention of acute kidney injury in patients undergoing on-pump cardiac surgery: a systematic review and meta-analysis. *Medicine* 95:e3465
287. Pei H, Wu Y, Wei Y, Yang Y, Teng S, Zhang H (2014) Remote ischemic preconditioning reduces perioperative cardiac and renal events in patients undergoing elective coronary intervention: a meta-analysis of 11 randomized trials. *PLoS One* 9:e115500
288. Li L, Li G, Yu C, Li Y (2013) The role of remote ischemic preconditioning on postoperative kidney injury in patients undergoing cardiac and vascular interventions: a meta-analysis. *J Cardiothorac Surg* 8:43
289. Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Hillis GS, Gallagher M, Jardine M (2016) Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. *BMJ* 355:i5599
290. Zhou CC, Ge YZ, Yao WT, Wu R, Xin H, Lu TZ, Li MH, Song KW, Wang M, Zhu YP, Zhu M, Geng LG, Gao XF, Zhou LH, Zhang SL, Zhu JG, Jia RP (2017) Limited clinical utility of remote ischemic conditioning in renal transplantation: a meta-analysis of randomized controlled trials. *PLoS One* 12:e0170729
291. Kolhe NV, Reilly T, Leung J, Fluck RJ, Swinscoe KE, Selby NM, Taal MW (2016) A simple care bundle for use in acute kidney injury: a propensity score-matched cohort study. *Nephrol Dial Transplant* 31:1846–1854
292. Joslin J, Wilson H, Zubli D, Gauge N, Kinirons M, Hopper A, Pile T, Ostermann M (2015) Recognition and management of acute kidney injury in hospitalised patients can be partially improved with the use of a care bundle. *Clinic Med (Lond)* 15:431–436
293. Bhagwanani A, Carpenter R, Yusuf A (2014) Improving the management of acute kidney injury in a district general hospital: introduction of the DONUT bundle. *BMJ Qual Improv Rep.* doi:10.1136/bmjquality.u202650.w1235
294. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A (2017) Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med.* doi:10.1007/s00134-016-4670-3
295. Angus DC, Barnato AE, Bell D, Bellomo R, Chong CR, Coats TJ, Davies A, Delaney A, Harrison DA, Holdgate A, Howe B, Huang DT, Iwashyna T, Kellum JA, Peake SL, Pike F, Reade MC, Rowan KM, Singer M, Webb SA, Weissfeld LA, Yealy DM, Young JD (2015) A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe investigators. *Intensive Care Med* 41:1549–1560
296. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup (2004) Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 8:R204–R212
297. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A (2007) Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 11:R31